Diacylglycerol	Diacylglycerol	NNP	O
kinases	kinase	NNS	O
DGKs	DGKs	NNP	O
are	be	VBP	O
a	a	DT	O
large	large	JJ	O
family	family	NN	O
of	of	IN	O
enzymes	enzyme	NNS	O
that	that	WDT	O
share	share	VBP	O
a	a	DT	O
common	common	JJ	O
catalytic	catalytic	JJ	O
activity	activity	NN	O
:	:	:	O
the	the	DT	O
phosphorylation	phosphorylation	NN	O
of	of	IN	O
diacylglycerol	diacylglycerol	NN	O
DAG	DAG	NNP	O
to	to	IN	O
phosphatidic	phosphatidic	JJ	O
acid	acid	NN	O
PA	PA	NNP	O
.	.	.	O

Remarkably	remarkably	RB	O
,	,	,	O
both	both	CC	O
the	the	DT	O
substrate	substrate	NN	O
DAG	DAG	NNP	O
and	and	CC	O
the	the	DT	O
product	product	NN	O
PA	PA	NNP	O
of	of	IN	O
the	the	DT	O
DGK	DGK	NNP	O
-	-	HYPH	O
catalysed	catalyse	VBN	O
reaction	reaction	NN	O
,	,	,	O
are	be	VBP	O
bioactive	bioactive	JJ	O
lipids	lipid	NNS	O
that	that	WDT	O
can	can	MD	O
act	act	VB	O
as	as	IN	O
second	second	JJ	O
messengers	messenger	NNS	B
.	.	.	O

DGK	DGK	NNP	O
activity	activity	NN	O
consequently	consequently	RB	O
serves	serve	VBZ	O
as	as	IN	O
a	a	DT	O
switch	switch	NN	O
to	to	TO	O
simultaneously	simultaneously	RB	O
dampen	dampen	VB	O
DAG	DAG	NNP	O
-	-	HYPH	O
mediated	mediate	VBN	O
signals	signal	NNS	O
and	and	CC	O
boost	boost	VB	O
PA	pa	NN	O
-	-	HYPH	O
mediated	mediate	VBN	O
signals	signal	NNS	B
.	.	.	O

Ten	ten	CD	O
mammalian	mammalian	JJ	O
DGK	DGK	NNP	O
isoforms	isoform	NNS	O
Î±	î±	NN	O
,	,	,	O
Î²	î²	NN	O
,	,	,	O
Î³	î³	NN	O
,	,	,	O
Î	Î	NNP	O
´	´	CD	O
,	,	,	O
Îµ	Îµ	NNP	O
,	,	,	O
Î¶	Î¶	NNP	O
,	,	,	O
Î	Î	NNP	O
·	·	NFP	O
,	,	,	O
Î¸	î¸	FW	O
,	,	,	O
Î¹	î¹	NN	O
,	,	,	O
and	and	CC	O
Ðº	Ðº	NNP	O
have	have	VBP	O
been	be	VBN	O
identified	identify	VBN	O
and	and	CC	O
divided	divide	VBN	O
into	into	IN	O
five	five	CD	O
groups	group	NNS	O
type	type	NN	O
IâV	IâV	NNP	O
according	accord	VBG	O
to	to	IN	O
their	-PRON-	PRP$	O
structural	structural	JJ	O
features	feature	NNS	B
,	,	,	B
.	.	.	O

The	the	DT	O
expression	expression	NN	O
of	of	IN	O
these	these	DT	O
isoforms	isoform	NNS	O
varies	vary	VBZ	O
depending	depend	VBG	O
on	on	IN	O
the	the	DT	O
cell	cell	NN	O
type	type	NN	O
.	.	.	O

Among	among	IN	O
the	the	DT	O
10	10	CD	O
isoforms	isoform	NNS	O
,	,	,	O
the	the	DT	O
Î±	Î±	NNP	O
isoform	isoform	NN	O
is	be	VBZ	O
among	among	IN	O
the	the	DT	O
most	most	RBS	O
studied	studied	JJ	O
and	and	CC	O
characterised	characterise	VBD	O
.	.	.	O

This	this	DT	O
kinase	kinase	NN	O
is	be	VBZ	O
highly	highly	RB	O
expressed	express	VBN	O
in	in	IN	O
the	the	DT	O
brain	brain	NN	O
,	,	,	O
spleen	spleen	NNS	O
,	,	,	O
and	and	CC	O
thymus	thymus	NN	O
and	and	CC	O
,	,	,	O
along	along	IN	O
with	with	IN	O
Î¸	Î¸	NNP	O
isoform	isoform	NN	O
,	,	,	O
in	in	IN	O
the	the	DT	O
bone	bone	NN	O
marrow	marrow	NN	O
.	.	.	O

This	this	DT	O
enzyme	enzyme	NNS	O
is	be	VBZ	O
also	also	RB	O
highly	highly	RB	O
expressed	express	VBN	O
in	in	IN	O
T	t	NN	O
-	-	HYPH	O
lymphocytes	lymphocyte	NNS	O
,	,	,	O
where	where	WRB	O
it	-PRON-	PRP	O
acts	act	VBZ	O
together	together	RB	O
with	with	IN	O
DGKÎ¶	DGKÎ¶	NNP	O
as	as	IN	O
negative	negative	JJ	O
regulator	regulator	NN	O
of	of	IN	O
the	the	DT	O
T	T	NNP	O
-	-	HYPH	O
cell	cell	NN	O
receptor	receptor	NN	O
TCR	TCR	NNP	O
response	response	NN	O
,	,	,	O
and	and	CC	O
a	a	DT	O
mediator	mediator	NN	O
of	of	IN	O
IL-2	IL-2	NNP	O
mediated	mediate	VBD	O
proliferation	proliferation	NN	B
,	,	,	B
.	.	.	O

The	the	DT	O
biological	biological	JJ	O
relevance	relevance	NN	O
of	of	IN	O
DGKÎ±	DGKÎ±	NNP	O
is	be	VBZ	O
best	well	RBS	O
demonstrated	demonstrate	VBN	O
in	in	IN	O
patients	patient	NNS	O
with	with	IN	O
X	X	NNS	O
-	-	HYPH	O
linked	link	VBN	O
lymphoproliferative	lymphoproliferative	JJ	O
disease	disease	NN	O
XLP-1	XLP-1	NNP	O
,	,	,	O
who	who	WP	O
experience	experience	VBP	O
life	life	NN	O
-	-	HYPH	O
threatening	threaten	VBG	O
,	,	,	O
uncontrolled	uncontrolled	JJ	O
accumulation	accumulation	NN	O
of	of	IN	O
CD8	CD8	NNP	O
+	+	NNP	O
T	T	NNP	O
cells	cell	NNS	O
in	in	IN	O
response	response	NN	O
to	to	IN	O
the	the	DT	O
EpsteinâBarr	EpsteinâBarr	NNP	O
virus	virus	NN	O
EBV	EBV	NNP	O
infection	infection	NN	B
.	.	.	O

In	in	IN	O
those	those	DT	O
patients	patient	NNS	O
,	,	,	O
germline	germline	JJ	O
mutations	mutation	NNS	O
of	of	IN	O
the	the	DT	O
adaptor	adaptor	NN	O
protein	protein	NN	O
SAP	SAP	NNP	O
SH2D1A	SH2D1A	NNP	O
perturb	perturb	VB	O
TCR	TCR	NNP	O
signalling	signalling	NN	O
and	and	CC	O
render	render	VB	O
DGKÎ±	DGKÎ±	NNP	O
constitutively	constitutively	RB	O
active	active	JJ	B
.	.	.	O

Deregulated	deregulate	VBN	O
DGKÎ±	DGKÎ±	NNP	O
activity	activity	NN	O
renders	render	VBZ	O
patient	patient	NN	O
-	-	HYPH	O
derived	derive	VBN	O
lymphocytes	lymphocyte	NNS	O
resistant	resistant	JJ	O
to	to	IN	O
reactivation	reactivation	NN	O
-	-	HYPH	O
induced	induce	VBN	O
cell	cell	NN	O
death	death	NN	O
RICD	RICD	NNP	O
.	.	.	O

Thus	thus	RB	O
,	,	,	O
antigen	antigen	NN	O
-	-	HYPH	O
activated	activate	VBN	O
lymphocytes	lymphocyte	NNS	O
accumulate	accumulate	VBP	O
in	in	IN	O
lymphonodes	lymphonodes	NN	O
and	and	CC	O
liver	liver	NN	O
,	,	,	O
resulting	result	VBG	O
in	in	IN	O
severe	severe	JJ	O
immunopathology	immunopathology	NN	B
.	.	.	O

Importantly	importantly	RB	O
,	,	,	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
restore	restore	VBP	O
RICD	RICD	NNP	O
sensitivity	sensitivity	NN	O
inÂ	inâ	NN	O
vitro	vitro	FW	O
and	and	CC	O
inÂ	inÂ	NNP	O
vivo	vivo	NNP	O
,	,	,	O
thus	thus	RB	O
avoiding	avoid	VBG	O
immunopathology	immunopathology	NN	O
and	and	CC	O
suggesting	suggest	VBG	O
a	a	DT	O
putative	putative	JJ	O
therapeutic	therapeutic	JJ	O
use	use	NN	O
of	of	IN	O
those	those	DT	O
molecules	molecule	NNS	O
in	in	IN	O
XLP-1	XLP-1	NNP	B
.	.	.	O

Apart	apart	RB	O
from	from	IN	O
T	t	NN	O
-	-	HYPH	O
cell	cell	NN	O
regulation	regulation	NN	O
,	,	,	O
DGKÎ±	DGKÎ±	NNP	O
also	also	RB	O
plays	play	VBZ	O
a	a	DT	O
role	role	NN	O
in	in	IN	O
cancer	cancer	NN	O
,	,	,	O
mediating	mediate	VBG	O
numerous	numerous	JJ	O
aspects	aspect	NNS	O
of	of	IN	O
cancer	cancer	NN	O
cell	cell	NN	O
progression	progression	NN	O
including	include	VBG	O
survival	survival	NN	B
,	,	,	B
,	,	,	O
migration	migration	NN	O
and	and	CC	O
invasion	invasion	NN	O
of	of	IN	O
cancer	cancer	NN	O
cells	cell	NNS	B
.	.	.	O

In	in	IN	O
particular	particular	JJ	O
,	,	,	O
it	-PRON-	PRP	O
has	have	VBZ	O
been	be	VBN	O
reported	report	VBN	O
that	that	IN	O
DGKÎ±	DGKÎ±	NNP	O
is	be	VBZ	O
over	over	RB	O
expressed	express	VBN	O
in	in	IN	O
hepatocellular	hepatocellular	JJ	O
carcinoma	carcinoma	NN	B
,	,	,	O
and	and	CC	O
melanoma	melanoma	NN	O
cells	cell	NNS	B
while	while	IN	O
other	other	JJ	O
reports	report	NNS	O
suggested	suggest	VBD	O
that	that	IN	O
the	the	DT	O
growth	growth	NN	O
of	of	IN	O
colon	colon	NN	O
and	and	CC	O
breast	breast	NN	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	O
was	be	VBD	O
significantly	significantly	RB	O
inhibited	inhibit	VBN	O
by	by	IN	O
DGKÎ±-siRNA	dgkî±-sirna	JJ	B
and	and	CC	O
DGKÎ±/atypical	DGKÎ±/atypical	NNP	O
PKC	PKC	NNP	O
/	/	SYM	O
Î²1	Î²1	NNP	O
integrin	integrin	NN	O
signalling	signal	VBG	O
pathway	pathway	NN	O
was	be	VBD	O
crucial	crucial	JJ	O
for	for	IN	O
matrix	matrix	NN	O
invasion	invasion	NN	O
of	of	IN	O
breast	breast	NN	O
carcinoma	carcinoma	NN	O
cells	cell	NNS	B
.	.	.	O

In	in	IN	O
addition	addition	NN	O
,	,	,	O
expression	expression	NN	O
is	be	VBZ	O
also	also	RB	O
higher	high	JJR	O
in	in	IN	O
lymphonodal	lymphonodal	NN	O
metastasis	metastasis	NN	O
than	than	IN	O
in	in	IN	O
breast	breast	NN	O
and	and	CC	O
gastric	gastric	JJ	O
original	original	JJ	O
tumour	tumour	NN	B
,	,	,	B
.	.	.	O

Finally	finally	RB	O
,	,	,	O
knock	knock	VB	O
down	down	IN	O
of	of	IN	O
DGKÎ±	DGKÎ±	NNP	O
impairs	impair	NNS	O
glioblastoma	glioblastoma	NN	O
tumorigenesis	tumorigenesis	NN	B
,	,	,	B
.	.	.	O

For	for	IN	O
all	all	PDT	O
these	these	DT	O
reasons	reason	NNS	O
,	,	,	O
the	the	DT	O
identification	identification	NN	O
of	of	IN	O
strong	strong	JJ	O
and	and	CC	O
selective	selective	JJ	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
,	,	,	O
it	-PRON-	PRP	O
is	be	VBZ	O
an	an	DT	O
important	important	JJ	O
field	field	NN	O
of	of	IN	O
research	research	NN	O
.	.	.	O

To	to	IN	O
date	date	NN	O
,	,	,	O
only	only	RB	O
a	a	DT	O
handful	handful	NN	O
of	of	IN	O
two	two	CD	O
-	-	HYPH	O
digit	digit	NN	O
micromolar	micromolar	JJ	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
DGKÎ±	DGKÎ±	NNP	O
have	have	VBP	O
been	be	VBN	O
identified	identify	VBN	O
,	,	,	O
but	but	CC	O
only	only	RB	O
three	three	CD	O
were	be	VBD	O
the	the	DT	O
most	most	RBS	O
characterised	characterised	JJ	O
,	,	,	O
namely	namely	RB	O
,	,	,	O
R59949	R59949	NNP	O
,	,	,	O
R59022	R59022	NNP	O
,	,	,	O
and	and	CC	O
ritanserin	ritanserin	NNP	O
Figure	Figure	NNP	O
1	1	CD	O
.	.	.	O

Three	three	CD	O
of	of	IN	O
the	the	DT	O
most	most	RBS	O
studied	studied	JJ	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

In	in	IN	O
our	-PRON-	PRP$	O
assay	assay	NN	O
system	system	NN	O
,	,	,	O
R59949	R59949	NNP	O
and	and	CC	O
R59022	R59022	NNP	O
have	have	VBP	O
an	an	DT	O
IC50	IC50	NNP	O
of	of	IN	O
11	11	CD	O
and	and	CC	O
20Â	20â	CD	O
ÂµM	ÂµM	NNP	O
,	,	,	O
respectively	respectively	RB	B
.	.	.	O

Their	-PRON-	PRP$	O
efficacy	efficacy	NN	O
has	have	VBZ	O
been	be	VBN	O
evaluated	evaluate	VBN	O
inÂ	inÂ	NNP	O
vivo	vivo	NN	O
studies	study	NNS	O
on	on	IN	O
mice	mouse	NNS	O
,	,	,	O
and	and	CC	O
is	be	VBZ	O
limited	limit	VBN	O
by	by	IN	O
their	-PRON-	PRP$	O
rapid	rapid	JJ	O
clearance	clearance	NN	O
t1/2	t1/2	NNP	O
=	=	SYM	O
â¼2âh	â¼2âh	NFP	O
)	)	-RRB-	B
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
these	these	DT	O
two	two	CD	O
inhibitors	inhibitor	NNS	O
are	be	VBP	O
also	also	RB	O
able	able	JJ	O
to	to	TO	O
target	target	VB	O
different	different	JJ	O
isoforms	isoform	NNS	O
of	of	IN	O
DGK	DGK	NNP	O
,	,	,	O
in	in	IN	O
particular	particular	JJ	O
R59022	R59022	NNP	O
acts	act	NNS	O
on	on	IN	O
type	type	NN	O
III	III	NNP	O
and	and	CC	O
V	V	NNP	O
Îµ	Îµ	NNP	O
e	e	NNP	O
Î¸	Î¸	NNP	O
,	,	,	O
while	while	IN	O
R59949	R59949	NNP	O

on	on	IN	O
type	type	NN	O
I	-PRON-	PRP	O
and	and	CC	O
II	II	NNP	O
Î³	î³	NN	O
,	,	,	O
Î	Î	NNP	O
´	´	CD	O
e	e	NN	O
Îº	Îº	NNP	O
)	)	-RRB-	B
,	,	,	B
and	and	CC	O
a	a	DT	O
study	study	NN	O
conducted	conduct	VBN	O
by	by	IN	O
Boroda	Boroda	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	.	O

recently	recently	RB	O
demonstrated	demonstrate	VBD	O
their	-PRON-	PRP$	O
strong	strong	JJ	O
antagonistic	antagonistic	JJ	O
activity	activity	NN	O
on	on	IN	O
5-HT2	5-ht2	CD	O
receptors	receptor	NNS	O
R59022	R59022	NNP	O
IC50	IC50	NNP	O
5HT2A=2.2ânM	5HT2A=2.2ânM	NNP	O
;	;	:	O
R5994	R5994	NNP	O
IC50	IC50	NNP	O
5HT2A=9.2ânM	5HT2A=9.2ânM	NNP	O
)	)	-RRB-	B
.	.	.	O

A	a	DT	O
search	search	NN	O
on	on	IN	O
ChEMBL	chembl	NN	O
database	database	NN	B
https://www.ebi.ac.uk/chembl/	https://www.ebi.ac.uk/chembl/	NN	O
show	show	VBP	O
how	how	WRB	O
these	these	DT	O
two	two	CD	O
molecules	molecule	NNS	O
have	have	VBP	O
activity	activity	NN	O
at	at	IN	O
the	the	DT	O
same	same	JJ	O
range	range	NN	O
of	of	IN	O
concentration	concentration	NN	O
with	with	IN	O
other	other	JJ	O
biological	biological	JJ	O
targets	target	NNS	O
,	,	,	O
behaving	behave	VBG	O
like	like	IN	O
a	a	DT	O
sort	sort	NN	O
of	of	IN	O
promiscuous	promiscuous	JJ	O
ligands	ligand	NNS	O
.	.	.	O

Ritanserin	Ritanserin	NNP	O
,	,	,	O
a	a	DT	O
well	well	RB	O
-	-	HYPH	O
known	know	VBN	O
serotoninergic	serotoninergic	JJ	O
antagonist	antagonist	NN	O
,	,	,	O
is	be	VBZ	O
structurally	structurally	RB	O
similar	similar	JJ	O
to	to	IN	O
R59022	R59022	NNP	O
,	,	,	O
differing	differ	VBG	O
for	for	IN	O
an	an	DT	O
H	H	NNP	O
-	-	HYPH	O
F	F	NNP	O
isosteric	isosteric	JJ	O
substitution	substitution	NN	O
on	on	IN	O
a	a	DT	O
phenyl	phenyl	NN	O
ring	ring	NN	O
.	.	.	O

Despite	despite	IN	O
this	this	DT	O
small	small	JJ	O
modification	modification	NN	O
,	,	,	O
Boroda	Boroda	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

showed	show	VBD	O
that	that	IN	O
ritanserin	ritanserin	NNP	O
was	be	VBD	O
a	a	DT	O
DGKÎ±	DGKÎ±	NNP	O
inhibitor	inhibitor	NN	O
IC50=15âÂµM	ic50=15ââµm	CD	O
more	more	RBR	O
potent	potent	JJ	O
than	than	IN	O
R59022	R59022	NNP	O
and	and	CC	O
R59949	R59949	NNP	O
and	and	CC	O
with	with	IN	O
a	a	DT	O
better	well	JJR	O
pharmacokinetic	pharmacokinetic	JJ	O
profile	profile	NN	O
t1/2=40âh	t1/2=40âh	NNS	O
in	in	IN	O
human	human	JJ	O
)	)	-RRB-	B
.	.	.	O

However	however	RB	O
,	,	,	O
the	the	DT	O
comparison	comparison	NN	O
of	of	IN	O
ritanserin	ritanserin	NNP	O
IC50	IC50	NNP	O
as	as	IN	O
serotonin	serotonin	NN	O
antagonist	antagonist	NN	O
and	and	CC	O
as	as	IN	O
DGKÎ±	DGKÎ±	NNP	O
inhibitor	inhibitor	NN	O
,	,	,	O
0.9ânM	0.9ânM	NNP	O
and	and	CC	O
15,000ânM	15,000ânm	CD	O
,	,	,	O
respectively	respectively	RB	O
,	,	,	O
reveal	reveal	VB	O
that	that	IN	O
ritanserin	ritanserin	NNP	O
is	be	VBZ	O
much	much	RB	O
a	a	DT	O
powerful	powerful	JJ	O
serotonin	serotonin	JJ	O
antagonist	antagonist	NN	O
than	than	IN	O
a	a	DT	O
DGK	DGK	NNP	O
inhibitor	inhibitor	NN	O
.	.	.	O

In	in	IN	O
addition	addition	NN	O
,	,	,	O
ritanserin	ritanserin	NNP	O
is	be	VBZ	O
also	also	RB	O
a	a	DT	O
potent	potent	JJ	O
inhibitor	inhibitor	NN	O
on	on	IN	O
dopaminergic	dopaminergic	JJ	O
receptors	receptor	NNS	O
with	with	IN	O
an	an	DT	O
IC50	IC50	NNP	O
of	of	IN	O
69ânM	69ânm	CD	B
.	.	.	O

Due	due	IN	O
to	to	IN	O
these	these	DT	O
drawbacks	drawback	NNS	O
,	,	,	O
at	at	IN	O
the	the	DT	O
beginning	beginning	NN	O
,	,	,	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
eliminate	eliminate	VB	O
the	the	DT	O
strong	strong	JJ	O
serotoninergic	serotoninergic	JJ	O
activity	activity	NN	O
of	of	IN	O
R59949	R59949	NNP	O
,	,	,	O
we	-PRON-	PRP	O
reasoned	reason	VBD	O
to	to	TO	O
replace	replace	VB	O
its	-PRON-	PRP$	O
protonable	protonable	JJ	O
nitrogen	nitrogen	NN	O
atom	atom	NN	O
,	,	,	O
which	which	WDT	O
at	at	IN	O
physiologically	physiologically	RB	O
pH	pH	NNP	O
mimics	mimic	NNS	O
the	the	DT	O
amino	amino	NN	O
group	group	NN	O
of	of	IN	O
serotonin	serotonin	NNP	O
,	,	,	O
with	with	IN	O
a	a	DT	O
carbon	carbon	NN	O
atom	atom	NN	O
.	.	.	O

We	-PRON-	PRP	O
decided	decide	VBD	O
therefore	therefore	RB	O
to	to	TO	O
synthesise	synthesise	VB	O
compound	compound	NN	O
1	1	CD	O
Figure	figure	NN	O
2	2	CD	O
see	see	VB	O
supporting	support	VBG	O
information	information	NN	O
for	for	IN	O
its	-PRON-	PRP$	O
synthesis	synthesis	NN	O
and	and	CC	O
a	a	DT	O
complete	complete	JJ	O
characterisation	characterisation	NN	O
and	and	CC	O
to	to	TO	O
test	test	VB	O
it	-PRON-	PRP	O
as	as	IN	O
DGKÎ±	DGKÎ±	NNP	O
inhibitor	inhibitor	NN	O
.	.	.	O

Interestingly	interestingly	RB	O
,	,	,	O
the	the	DT	O
compound	compound	NN	O
was	be	VBD	O
totally	totally	RB	O
devoid	devoid	JJ	O
of	of	IN	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
on	on	IN	O
the	the	DT	O
enzyme	enzyme	NNS	O
,	,	,	O
showing	show	VBG	O
the	the	DT	O
importance	importance	NN	O
of	of	IN	O
the	the	DT	O
basic	basic	JJ	O
nitrogen	nitrogen	NN	O
atom	atom	NN	O
not	not	RB	O
only	only	RB	O
for	for	IN	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
serotoninergic	serotoninergic	JJ	O
activity	activity	NN	O
,	,	,	O
but	but	CC	O
also	also	RB	O
for	for	IN	O
the	the	DT	O
interaction	interaction	NN	O
with	with	IN	O
the	the	DT	O
kinase	kinase	NN	O
.	.	.	O

With	with	IN	O
this	this	DT	O
in	in	IN	O
mind	mind	NN	O
,	,	,	O
we	-PRON-	PRP	O
recently	recently	RB	O
used	use	VBD	O
an	an	DT	O
in	in	IN	O
-	-	HYPH	O
silico	silico	NN	O
approach	approach	NN	O
based	base	VBN	O
on	on	IN	O
chemical	chemical	NN	O
homology	homology	NN	O
with	with	IN	O
the	the	DT	O
two	two	CD	O
commercially	commercially	RB	O
available	available	JJ	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
R59022	R59022	NNP	O
and	and	CC	O
R59949	R59949	NNP	O
using	use	VBG	O
the	the	DT	O
programmes	programme	NNS	O
ROCS	rocs	VBP	B
and	and	CC	O
EON	EON	NNP	B
.	.	.	O

From	from	IN	O
this	this	DT	O
study	study	NN	O
,	,	,	O
we	-PRON-	PRP	O
identified	identify	VBD	O
a	a	DT	O
compound	compound	NN	O
,	,	,	O
Amb639752	Amb639752	NNP	O
Figure	figure	NN	O
2	2	CD	O
,	,	,	O
featuring	feature	VBG	O
a	a	DT	O
lower	low	JJR	O
IC50	IC50	NNP	O
for	for	IN	O
DGKÎ±	DGKÎ±	NNP	O
than	than	IN	O
ritanserin	ritanserin	NNP	O
IC50=17Â	ic50=17â	RB	O
ÂµM	ÂµM	NNP	O
,	,	,	O
a	a	DT	O
better	well	JJR	O
selectivity	selectivity	NN	O
for	for	IN	O
the	the	DT	O
Î±-isoform	î±-isoform	NN	O
and	and	CC	O
devoid	devoid	JJ	O
of	of	IN	O
anti	anti	JJ	O
-	-	JJ	O
serotoninergic	serotoninergic	JJ	O
activity	activity	NN	O
.	.	.	O

Along	along	IN	O
with	with	IN	O
CU-3	CU-3	NNP	O
,	,	,	O
which	which	WDT	O
features	feature	VBZ	O
an	an	DT	O
IC50	IC50	NNP	O
of	of	IN	O
0.6Â	0.6Â	NNP	O
ÂµM	ÂµM	NNP	O
on	on	IN	O
DGKÎ±	DGKÎ±	NNP	B
but	but	CC	O
contains	contain	VBZ	O
a	a	DT	O
reactive	reactive	JJ	O
Michael	Michael	NNP	O
acceptor	acceptor	NN	B
,	,	,	O
Amb639752	Amb639752	NNP	O
is	be	VBZ	O
the	the	DT	O
most	most	RBS	O
effective	effective	JJ	O
pharmacological	pharmacological	JJ	O
tool	tool	NN	O
available	available	JJ	O
to	to	TO	O
study	study	VB	O
DGKÎ±	DGKÎ±	NNP	B
.	.	.	O

In	in	IN	O
this	this	DT	O
manuscript	manuscript	NN	O
,	,	,	O
we	-PRON-	PRP	O
report	report	VBP	O
the	the	DT	O
structureâactivity	structureâactivity	NN	O
studies	study	NNS	O
on	on	IN	O
Amb639752	Amb639752	NNP	O
and	and	CC	O
,	,	,	O
in	in	IN	O
combination	combination	NN	O
with	with	IN	O
data	datum	NNS	O
on	on	IN	O
ritanserin	ritanserin	NNP	O
,	,	,	O
the	the	DT	O
generation	generation	NN	O
of	of	IN	O
a	a	DT	O
pharmacophore	pharmacophore	NN	O
model	model	NN	O
for	for	IN	O
this	this	DT	O
class	class	NN	O
of	of	IN	O
compounds	compound	NNS	O
,	,	,	O
which	which	WDT	O
could	could	MD	O
be	be	VB	O
useful	useful	JJ	O
for	for	IN	O
the	the	DT	O
identification	identification	NN	O
of	of	IN	O
other	other	JJ	O
potential	potential	NN	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

Commercially	commercially	RB	O
available	available	JJ	O
reagents	reagent	NNS	O
and	and	CC	O
solvents	solvent	NNS	O
were	be	VBD	O
used	use	VBN	O
without	without	IN	O
further	further	JJ	O
purification	purification	NN	O
.	.	.	O

Toluene	Toluene	NNP	O
were	be	VBD	O
distilled	distil	VBN	O
immediately	immediately	RB	O
before	before	IN	O
use	use	NN	O
from	from	IN	O
Na	Na	NNP	O
/	/	SYM	O
benzophenone	benzophenone	NN	O
under	under	IN	O
a	a	DT	O
slight	slight	JJ	O
positive	positive	JJ	O
atmosphere	atmosphere	NN	O
of	of	IN	O
dry	dry	JJ	O
nitrogen	nitrogen	NN	O
.	.	.	O

Dichloromethane	Dichloromethane	NNP	O
was	be	VBD	O
dried	dry	VBN	O
by	by	IN	O
distillation	distillation	NN	O
from	from	IN	O
P2O5	P2O5	NNP	O
and	and	CC	O
stored	store	VBN	O
on	on	RP	O
activated	activate	VBN	O
molecular	molecular	JJ	O
sieves	sieve	NNS	O
4Â	4â	IN	O
Ã	Ã	NNP	O
		_SP	O
.	.	.	O

When	when	WRB	O
needed	need	VBD	O
the	the	DT	O
reactions	reaction	NNS	O
were	be	VBD	O
performed	perform	VBN	O
in	in	IN	O
flame-	flame-	NN	O
or	or	CC	O
oven	oven	NN	O
-	-	HYPH	O
dried	dry	VBN	O
glassware	glassware	NN	O
under	under	IN	O
a	a	DT	O
positive	positive	JJ	O
pressure	pressure	NN	O
of	of	IN	O
dry	dry	JJ	O
nitrogen	nitrogen	NN	O
.	.	.	O

Melting	melt	VBG	O
points	point	NNS	O
were	be	VBD	O
determined	determine	VBN	O
in	in	IN	O
open	open	JJ	O
glass	glass	NN	O
capillary	capillary	NN	O
with	with	IN	O
a	a	DT	O
Stuart	Stuart	NNP	O
scientific	scientific	JJ	O
SMP3	smp3	NN	O
apparatus	apparatus	NN	O
and	and	CC	O
are	be	VBP	O
uncorrected	uncorrected	JJ	O
.	.	.	O

All	all	DT	O
compounds	compound	NNS	O
were	be	VBD	O
checked	check	VBN	O
by	by	IN	O
IR	IR	NNP	O
FT	FT	NNP	O
-	-	HYPH	O
IR	IR	NNP	O
THERMO	THERMO	NNP	O
-	-	HYPH	O
NICOLET	NICOLET	NNP	O
AVATAR	AVATAR	NNP	O
,	,	,	O
1H	1H	NNP	O
and	and	CC	O
13C	13c	CD	O
APT	APT	NNP	O
JEOL	JEOL	NNP	O
ECP	ECP	NNP	O
300âMHz	300âmhz	RB	O
spectrometer	spectrometer	VBP	O
,	,	,	O
and	and	CC	O
mass	mass	NN	O
spectrometry	spectrometry	NN	O
Thermo	Thermo	NNP	O
Finningan	Finningan	NNP	O
LCQ	LCQ	NNP	O
-	-	HYPH	O
deca	deca	NN	O
XP	xp	NN	O
-	-	HYPH	O
plus	plus	CC	O
,	,	,	O
San	San	NNP	O
Jose	Jose	NNP	O
,	,	,	O
CA	CA	NNP	O
equipped	equip	VBD	O
with	with	IN	O
an	an	DT	O
ESI	ESI	NNP	O
source	source	NN	O
and	and	CC	O
an	an	DT	O
ion	ion	NN	O
trap	trap	NN	O
detector	detector	NN	O
.	.	.	O

Chemical	chemical	NN	O
shifts	shift	NNS	O
are	be	VBP	O
reported	report	VBN	O
in	in	IN	O
parts	part	NNS	O
per	per	IN	O
million	million	CD	O
ppm	ppm	NN	O
.	.	.	O

Flash	flash	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
was	be	VBD	O
performed	perform	VBN	O
on	on	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
Merck	Merck	NNP	O
Kieselgel	Kieselgel	NNP	O
60	60	CD	O
,	,	,	O
230â400Â	230â400â	CD	O
mesh	mesh	VBP	O
ASTM	ASTM	NNP	O
,	,	,	O
Kenilworth	Kenilworth	NNP	O
,	,	,	O
NJ	NJ	NNP	O
.	.	.	O

Thin	thin	JJ	O
layer	layer	NN	O
chromatography	chromatography	NN	O
TLC	TLC	NNP	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
on	on	IN	O
5âÃâ20âcm	5âãâ20âcm	CD	O
plates	plate	NNS	O
with	with	IN	O
a	a	DT	O
layer	layer	NN	O
thickness	thickness	NN	O
of	of	IN	O
0.25âmm	0.25âmm	NNP	O
Merck	Merck	NNP	O
Silica	Silica	NNP	O
gel	gel	VBD	O
60	60	CD	O
F254	F254	NNP	O
,	,	,	O
Kenilworth	Kenilworth	NNP	O
,	,	,	O
NJ	NJ	NNP	O
.	.	.	O

When	when	WRB	O
necessary	necessary	JJ	O
they	-PRON-	PRP	O
were	be	VBD	O
developed	develop	VBN	O
with	with	IN	O
KMnO4	kmno4	NN	O
reagent	reagent	NN	O
.	.	.	O

Purity	purity	NN	O
of	of	IN	O
tested	test	VBN	O
compounds	compound	NNS	O
was	be	VBD	O
established	establish	VBN	O
by	by	IN	O
elemental	elemental	JJ	O
analysis	analysis	NN	O
.	.	.	O

Elemental	elemental	JJ	O
analysis	analysis	NN	O
C	c	NN	O
,	,	,	O
H	h	NN	O
,	,	,	O
N	n	CD	O
of	of	IN	O
the	the	DT	O
target	target	NN	O
compounds	compound	NNS	O
is	be	VBZ	O
within	within	IN	O
Â±0.4	â±0.4	ADD	O
%	%	NN	O
of	of	IN	O
the	the	DT	O
calculated	calculate	VBN	O
values	value	NNS	O
,	,	,	O
confirming	confirm	VBG	O
â¥95	â¥95	NNP	O
%	%	NN	O
purity	purity	NN	O
.	.	.	O

In	in	IN	O
a	a	DT	O
Schlenk	Schlenk	NNP	O
tube	tube	NN	O
,	,	,	O
under	under	IN	O
nitrogen	nitrogen	NN	O
,	,	,	O
2,6-dimethyl-1H	2,6-dimethyl-1h	CD	O
-	-	HYPH	O
indole	indole	NN	O
3	3	CD	O
0.20âg	0.20âg	NN	O
,	,	,	O
1.38âmmol	1.38âmmol	NNP	O
,	,	,	O
1Â	1â	NN	O
eq	eq	NNP	O
was	be	VBD	O
dissolved	dissolve	VBN	O
in	in	IN	O
4âmL	4âml	CD	O
of	of	IN	O
dichloroethane	dichloroethane	NNP	O
dry	dry	NNP	O
and	and	CC	O
0.25âmL	0.25âml	NN	O
of	of	IN	O
DBU	DBU	NNP	O
1.66âmmol	1.66âmmol	CD	O
,	,	,	O
1.2Â	1.2â	NN	O
eq	eq	NNP	O
were	be	VBD	O
added	add	VBN	O
.	.	.	O

The	the	DT	O
resulting	result	VBG	O
solution	solution	NN	O
was	be	VBD	O
heated	heat	VBN	O
at	at	IN	O
90âÂ	90ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

When	when	WRB	O
reached	reach	VBD	O
this	this	DT	O
temperature	temperature	NN	O
,	,	,	O
chloroacetyl	chloroacetyl	NN	O
chloride	chloride	NN	O
4	4	CD	O
0.12âmL	0.12âml	NN	O
,	,	,	O
1.52âmmol	1.52âmmol	NNP	O
,	,	,	O
1.1Â	1.1â	NN	O
eq	eq	NNP	O
was	be	VBD	O
added	add	VBN	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
stirred	stir	VBN	O
for	for	IN	O
30âmin	30âmin	NN	O
,	,	,	O
then	then	RB	O
solvent	solvent	NN	O
was	be	VBD	O
evaporated	evaporate	VBN	O
and	and	CC	O
the	the	DT	O
crude	crude	NN	O
purified	purify	VBN	O
by	by	IN	O
column	column	NN	O
chromatography	chromatography	NN	O
using	use	VBG	O
PE	PE	NNP	O
/	/	SYM	O
EtOAc	EtOAc	NNS	O
7:3	7:3	CD	O
and	and	CC	O
PE	PE	NNP	O
/	/	SYM	O
EtOAc	EtOAc	NNP	O
5:5	5:5	CD	O
as	as	IN	O
eluants	eluant	NNS	O
to	to	TO	O
give	give	VB	O
270âmg	270âmg	CD	O
of	of	IN	O
product	product	NN	O
as	as	IN	O
violet	violet	NN	O
solid	solid	RB	O
:	:	:	O
yield	yield	VB	O
90	90	CD	O
%	%	NN	O
;	;	:	O
m.p	m.p	NNP	O
.	.	NNP	O

243.7â244.2âÂ	243.7â244.2âÂ	NNP	O
°	°	,	O
C	C	NNP	O
;	;	:	O
1H	1H	NNP	O
NMR	NMR	NNP	O
300âMHz	300âmhz	CD	O
,	,	,	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
11.88	11.88	CD	O

br	br	NNP	O
s	s	NNP	O
,	,	,	O
NH	NH	NNP	O
,	,	,	O
7.85	7.85	CD	O
d	d	NNP	O
,	,	,	O
Jâ=â7.9âHz	jâ=â7.9âhz	NN	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
7.18	7.18	CD	O
s	s	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
6.99	6.99	CD	O
d	d	NN	O
,	,	,	O
Jâ=â8.0âHz	Jâ=â8.0âHz	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
4.89	4.89	CD	O
s	s	NNP	O
,	,	,	O
2H	2H	NNP	O
,	,	,	O
2.68	2.68	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
2.39	2.39	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
.	.	.	O

MS	MS	NNP	O
ESI	ESI	NNP	O
m	m	NNP	O
/	/	SYM	O
z	z	NNP	O
:	:	:	O
222	222	CD	O
Mâ+âH]+	mâ+âh]+	RB	O
.	.	.	O

Two	two	CD	O
hundred	hundred	CD	O
and	and	CC	O
fifteen	fifteen	CD	O
milligrams	milligram	NNS	O
of	of	IN	O
6	6	CD	O
0.58âmmol	0.58âmmol	JJ	O
,	,	,	O
1Â	1â	NN	O
eq	eq	NNP	O
were	be	VBD	O
dissolved	dissolve	VBN	O
in	in	IN	O
dichloromethane	dichloromethane	NNP	O
dry	dry	JJ	O
.	.	.	O

The	the	DT	O
resulting	result	VBG	O
solution	solution	NN	O
was	be	VBD	O
cooled	cool	VBN	O
at	at	IN	O
0âÂ	0ââ	CD	O
°	°	NNP	O
C	C	NNP	O
and	and	CC	O
0.69âmL	0.69âml	NN	O
of	of	IN	O
trifluoroacetic	trifluoroacetic	JJ	O
acid	acid	NN	O
9.28âmmol	9.28âmmol	CD	O
,	,	,	O
16Â	16â	CD	O
eq	eq	NNP	O
was	be	VBD	O
added	add	VBN	O
.	.	.	O

After	after	IN	O
3âh	3âh	CD	O
,	,	,	O
the	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
worked	work	VBN	O
up	up	RP	O
adding	add	VBG	O
NaOH	NaOH	NNP	O
2Â	2â	NN	O
M	m	NN	O
solution	solution	NN	O
until	until	IN	O
pH	pH	NNP	O
=	=	SYM	O
12	12	CD	O
.	.	.	O

Then	then	RB	O
,	,	,	O
NaCl	NaCl	NNP	O
solid	solid	JJ	O
was	be	VBD	O
added	add	VBN	O
and	and	CC	O
the	the	DT	O
solution	solution	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
THF	THF	NNP	O
x2	x2	NNP	O
.	.	.	O

The	the	DT	O
combined	combined	JJ	O
organic	organic	JJ	O
phases	phase	NNS	O
were	be	VBD	O
dried	dry	VBN	O
on	on	IN	O
sodium	sodium	NN	O
sulphate	sulphate	NN	O
.	.	.	O

After	after	IN	O
evaporation	evaporation	NN	O
of	of	IN	O
the	the	DT	O
solvent	solvent	NN	O
,	,	,	O
the	the	DT	O
crude	crude	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
column	column	NN	O
chromatography	chromatography	NN	O
using	use	VBG	O
EtOAc	EtOAc	NNP	O
/	/	SYM	O
MeOH	MeOH	NNP	O
9:1	9:1	NNP	O
and	and	CC	O
MeCN	MeCN	NNP	O
/	/	SYM	O
NH3	NH3	NNP	O
9:1	9:1	CD	O
as	as	IN	O
eluants	eluant	NNS	O
to	to	TO	O
give	give	VB	O
103âmg	103âmg	CD	O
of	of	IN	O
the	the	DT	O
product	product	NN	O
as	as	IN	O
yellowish	yellowish	JJ	O
solid	solid	JJ	O
:	:	:	O
yield	yield	NN	O
:	:	:	O
65	65	CD	O
%	%	NN	O
;	;	:	O
m.p	m.p	NNP	O
.	.	NNP	O

:	:	:	O
232.9â233.6âÂ	232.9â233.6âÂ	NNP	O
°	°	,	O
C	C	NNP	O
;	;	:	O
1H	1H	NNP	O
NMR	NMR	NNP	O
300âMHz	300âmhz	CD	O
,	,	,	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
11.79	11.79	CD	O
br	br	NNP	O
s	s	NNP	O
,	,	,	O
NH	NH	NNP	O
,	,	,	O
7.85	7.85	CD	O
d	d	NNP	O
,	,	,	O
Jâ=â7.9âHz	jâ=â7.9âhz	NN	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
7.15	7.15	CD	O
s	s	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
6.95	6.95	CD	O
d	d	NN	O
,	,	,	O
Jâ=â8.2âHz	jâ=â8.2âhz	NN	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
3.83(br	3.83(br	CD	O
s	s	POS	O
,	,	,	O
4H	4H	NNP	O
,	,	,	O
3.62	3.62	CD	O
s	s	NNP	O
,	,	,	O
2H	2H	NNP	O
,	,	,	O
2.86	2.86	CD	O
br	br	NNP	O
s	s	NNP	O
,	,	,	O
4H	4H	NNP	O
,	,	,	O
2.67	2.67	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
2.38	2.38	CD	O
s	s	NN	O
,	,	,	O
3H	3H	NNP	O
;	;	:	O
IR	IR	NNP	O
KBr	KBr	NNP	O
:	:	:	O
3446	3446	CD	O
,	,	,	O
3181	3181	CD	O
,	,	,	O
2813	2813	CD	O
,	,	,	O
1634	1634	CD	O
,	,	,	O
1455	1455	CD	O
,	,	,	O
1330	1330	CD	O
,	,	,	O
821	821	CD	O

Î½max	Î½max	NNP	O
/	/	SYM	O
cmâ1	cmâ1	NNP	O
;	;	:	O
MS	MS	NNP	O
ESI	ESI	NNP	O
m	m	NNP	O
/	/	SYM	O
z	z	NNP	O
:	:	:	O
272	272	CD	O

Mâ+âH]+.1-(2,6-Dimethyl-1H	Mâ+âH]+.1-(2,6-Dimethyl-1H	NNP	O
-	-	HYPH	O
indol-3-yl)-2-(piperazin-1-yl)ethan-1-one	indol-3-yl)-2-(piperazin-1-yl)ethan-1-one	NNP	O
7	7	CD	O
1Â	1â	NN	O
eq	eq	NNP	O
was	be	VBD	O
dissolved	dissolve	VBN	O
in	in	IN	O
dichloromethane	dichloromethane	NNP	O
dry	dry	JJ	O
.	.	.	O

To	to	IN	O
the	the	DT	O
resulting	result	VBG	O
solution	solution	NN	O
EDCI	EDCI	NNP	O
1Â	1â	NN	O
eq	eq	NNP	O
,	,	,	O
TEA	TEA	NNP	O
2Â	2Â	NNS	O
eq	eq	NNP	O
,	,	,	O
DMAP	DMAP	NNP	O
0.1Â	0.1Â	NNP	O
eq	eq	NNP	O
and	and	CC	O
the	the	DT	O
appropriate	appropriate	JJ	O
carboxylic	carboxylic	JJ	O
acid	acid	NN	O
1Â	1â	NN	O
eq	eq	NNP	O
were	be	VBD	O
sequentially	sequentially	RB	O
added	add	VBN	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
stirred	stir	VBN	O
under	under	IN	O
nitrogen	nitrogen	NN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
overnight	overnight	RB	O
.	.	.	O

Evaporation	evaporation	NN	O
of	of	IN	O
the	the	DT	O
solvent	solvent	NN	O
gave	give	VBD	O
a	a	DT	O
crude	crude	NN	O
which	which	WDT	O
was	be	VBD	O
directly	directly	RB	O
purified	purify	VBN	O
by	by	IN	O
column	column	NN	O
chromatography	chromatography	NN	O
.	.	.	O

Madin	Madin	NNP	O
-	-	HYPH	O
Darby	Darby	NNP	O
canine	canine	NN	O
kidney	kidney	NN	O
MDCK	MDCK	NNP	O
cells	cell	NNS	O
stably	stably	RB	O
expressing	express	VBG	O
One	one	CD	O
Strep	Strep	NNP	O
Tag	Tag	NNP	O
DGKÎ±	DGKÎ±	NNP	O
OST	OST	NNP	O
-	-	HYPH	O
DGKÎ±	DGKÎ±	NNP	O
were	be	VBD	O
prepared	prepare	VBN	O
by	by	IN	O
infecting	infect	VBG	O
MDCK	MDCK	NNP	O
cells	cell	NNS	O
with	with	IN	O
a	a	DT	O
vector	vector	NN	O
expressing	express	VBG	O
an	an	DT	O
inducible	inducible	JJ	O
OST	OST	NNP	O
tagged	tag	VBN	O
DGKÎ±	DGKÎ±	NNP	O
constructs	construct	NNS	B
.	.	.	O

MDCK	mdck	NN	O
cells	cell	NNS	O
infected	infect	VBN	O
with	with	IN	O
empty	empty	JJ	O
vector	vector	NN	O
were	be	VBD	O
used	use	VBN	O
as	as	IN	O
controls	control	NNS	O
.	.	.	O

MDCK	mdck	NN	O
cells	cell	NNS	O
were	be	VBD	O
cultured	culture	VBN	O
in	in	IN	O
MEM	MEM	NNP	O
minimal	minimal	JJ	O
essential	essential	JJ	O
medium	medium	NN	O
with	with	IN	O
5	5	CD	O
%	%	NN	O
FBS	FBS	NNP	O
foetal	foetal	JJ	O
bovine	bovine	JJ	O
serum	serum	NN	O
and	and	CC	O
1	1	CD	O
%	%	NN	O
antibioticâantimycotic	antibioticâantimycotic	NN	O
solution	solution	NN	O
.	.	.	O

Routinely	routinely	RB	O
,	,	,	O
cells	cell	NNS	O
were	be	VBD	O
splitted	splitte	VBN	O
every	every	DT	O
3â4Â	3â4â	CD	O
days	day	NNS	O
with	with	IN	O
trypsinâEDTA	trypsinâEDTA	NNP	O
0.25	0.25	CD	O
%	%	NN	O
in	in	IN	O
standard	standard	JJ	O
100âmm	100âmm	CD	O
dishes	dish	NNS	O
.	.	.	O

Human	human	JJ	O
embryonic	embryonic	JJ	O
kidney	kidney	NN	O
293	293	CD	O
T	t	NN	O
cells	cell	NNS	O
10âcm2	10âcm2	CD	O
plates	plate	NNS	O
were	be	VBD	O
cultured	culture	VBN	O
in	in	IN	O
RPMI	RPMI	NNP	O
with	with	IN	O
10	10	CD	O
%	%	NN	O
FBS	FBS	NNP	O
and	and	CC	O
1	1	CD	O
%	%	NN	O
penicillin	penicillin	NN	O
/	/	SYM	O
streptomycin	streptomycin	NNS	O
and	and	CC	O
cultures	culture	NNS	O
were	be	VBD	O
maintained	maintain	VBN	O
by	by	IN	O
splitting	split	VBG	O
them	-PRON-	PRP	O
for	for	IN	O
every	every	DT	O
2â3Â	2â3â	CD	O
days	day	NNS	O
using	use	VBG	O
trypsinâEDTA	trypsinâEDTA	NNP	O
0.25	0.25	CD	O
%	%	NN	O
.	.	.	O

Michigan	Michigan	NNP	O
Cancer	Cancer	NNP	O
Foundation	Foundation	NNP	O
7	7	CD	O
MCF7	MCF7	NNP	O
cells	cell	NNS	O
were	be	VBD	O
cultured	culture	VBN	O
in	in	IN	O
DMEM	DMEM	NNP	O
with	with	IN	O
10	10	CD	O
%	%	NN	O
FBS	fbs	NN	O
+	+	SYM	O
1	1	CD	O
%	%	NN	O
penicillin	penicillin	NN	O
/	/	SYM	O
streptomycin	streptomycin	NNS	O
and	and	CC	O
cultures	culture	NNS	O
were	be	VBD	O
maintained	maintain	VBN	O
by	by	IN	O
splitting	split	VBG	O
them	-PRON-	PRP	O
for	for	IN	O
every	every	DT	O
2â3Â	2â3â	CD	O
days	day	NNS	O
using	use	VBG	O
trypsinâEDTA	trypsinâEDTA	NNP	O
0.25	0.25	CD	O
%	%	NN	O
.	.	.	O

PBL	PBL	NNP	O
were	be	VBD	O
isolated	isolate	VBN	O
from	from	IN	O
healthy	healthy	JJ	O
anonymous	anonymous	JJ	O
human	human	JJ	O
donors	donor	NNS	O
by	by	IN	O
Ficoll	Ficoll	NNP	O
-	-	HYPH	O
Paque	Paque	NNP	O
PLUS	PLUS	NNP	O
GE	GE	NNP	O
Healthcare	Healthcare	NNP	O
,	,	,	O
Chicago	Chicago	NNP	O
,	,	,	O
IL	IL	NNP	O
density	density	NN	O
gradient	gradient	NN	O
centrifugation	centrifugation	NNP	O
,	,	,	O
washed	wash	VBD	O
,	,	,	O
and	and	CC	O
resuspended	resuspend	VBD	O
at	at	IN	O
2âÃâ106	2âãâ106	CD	O
cell	cell	NN	O
/	/	SYM	O
mL	ml	NN	O
in	in	IN	O
RPMI	RPMI	NNP	O
-	-	:	O
GlutaMAX	GlutaMAX	NNP	O
containing	contain	VBG	O
10	10	CD	O
%	%	NN	O
heat	heat	NN	O
inactivated	inactivate	VBD	O
FCS	FCS	NNP	O
,	,	,	O
2âmM	2âmm	CD	O
glutamine	glutamine	NN	O
,	,	,	O
and	and	CC	O
100âU	100âU	NNP	O
/	/	SYM	O
mL	mL	NNP	O
of	of	IN	O
penicillin	penicillin	NNP	O
and	and	CC	O
streptomycin	streptomycin	NN	O
.	.	.	O

T	t	NN	O
cells	cell	NNS	O
were	be	VBD	O
activated	activate	VBN	O
with	with	IN	O
1âÂµg	1âÂµg	NNP	O
/	/	SYM	O
mL	mL	NNP	O
anti	anti	JJ	O
-	-	NNP	O
CD3	cd3	JJ	O
UCHT1	UCHT1	NNP	O
and	and	CC	O
anti	anti	NNP	O
-	-	NNP	O
CD28	CD28	NNP	O
clone	clone	NNP	O
CD28.2	cd28.2	NN	O
antibodies	antibodie	VBZ	O
.	.	.	O

After	after	IN	O
threeÂ	threeÂ	NNP	O
days	day	NNS	O
,	,	,	O
activated	activate	VBD	O
T	t	NN	O
cells	cell	NNS	O
were	be	VBD	O
washed	wash	VBN	O
and	and	CC	O
cultured	culture	VBN	O
in	in	IN	O
medium	medium	NN	O
additionated	additionate	VBN	O
of	of	IN	O
100âIU	100âiu	CD	O
/	/	SYM	O
mL	mL	NNP	O
rhIL-2	rhil-2	ADD	O

Peprotech	Peprotech	NNP	O
,	,	,	O
Rocky	Rocky	NNP	O
Hill	Hill	NNP	O
,	,	,	O
NJ	NJ	NNP	O
at	at	IN	O
1.2âÃâ106	1.2âÃâ106	NNP	O
cells	cell	NNS	O
/	/	SYM	O
mL	mL	NNP	O
for	for	IN	O
â¥7Â	â¥7Â	NNP	O
days	day	NNS	O
by	by	IN	O
changing	change	VBG	O
media	medium	NNS	O
for	for	IN	O
every	every	DT	O
2â3Â	2â3â	CD	O
days	day	NNS	O
.	.	.	O

Human	human	JJ	O
monocytes	monocyte	NNS	O
were	be	VBD	O
isolated	isolate	VBN	O
from	from	IN	O
healthy	healthy	JJ	O
anonymous	anonymous	JJ	O
human	human	JJ	O
buffy	buffy	NNP	O
coats	coat	NNS	O
provided	provide	VBN	O
by	by	IN	O
the	the	DT	O
Transfusion	Transfusion	NNP	O
Service	Service	NNP	O
of	of	IN	O
Ospedale	Ospedale	NNP	O
Maggiore	Maggiore	NNP	O
della	della	NN	O
CaritÃ	CaritÃ	NNP	O
,	,	,	O
Novara	Novara	NNP	O
,	,	,	O
Italy	Italy	NNP	O
by	by	IN	O
the	the	DT	O
standard	standard	JJ	O
technique	technique	NN	O
of	of	IN	O
dextran	dextran	NN	O
sedimentation	sedimentation	NN	O
and	and	CC	O
Histopaque	Histopaque	NNP	O
density	density	NN	O
=	=	SYM	O
1.077âgÂ	1.077âgâ	CD	O
cm3	cm3	NNS	O
,	,	,	O
Sigma	Sigma	NNP	O
-	-	HYPH	O
Aldrich	Aldrich	NNP	O
,	,	,	O
Milano	Milano	NNP	O
,	,	,	O
Italy	Italy	NNP	O
gradient	gradient	NN	O
centrifugation	centrifugation	NNP	O
400Ãg	400ãg	CD	O
,	,	,	O
30âmin	30âmin	NN	O
,	,	,	O
room	room	NN	O
temperature	temperature	NN	O
and	and	CC	O
recovered	recover	VBN	O
by	by	IN	O
fine	fine	JJ	O
suction	suction	NN	O
at	at	IN	O
the	the	DT	O
interface	interface	NN	O
,	,	,	O
as	as	IN	O
described	describe	VBN	O
previously	previously	RB	B
.	.	.	O

Purified	purified	JJ	O
monocytes	monocyte	NNS	O
populations	population	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
by	by	IN	O
adhesion	adhesion	NN	O
90âmin	90âmin	NNP	O
,	,	,	O
37âÂ	37âÂ	NNP	O
°	°	,	O
C	C	NNP	O
,	,	,	O
5	5	CD	O
%	%	NN	O
CO2	CO2	NNP	O
in	in	IN	O
serum	serum	NN	O
-	-	HYPH	O
free	free	JJ	O
RPMI	RPMI	NNP	O
1640	1640	CD	O
medium	medium	NN	O
Sigma	Sigma	NNP	O
-	-	HYPH	O
Aldrich	Aldrich	NNP	O
,	,	,	O
Milano	Milano	NNP	O
,	,	,	O
Italy	Italy	NNP	O
supplemented	supplement	VBD	O
with	with	IN	O
2âmM	2âmm	CD	O
glutamine	glutamine	NN	O
and	and	CC	O
antibiotics	antibiotic	NNS	O
.	.	.	O

Cell	cell	NN	O
viability	viability	NN	O
trypan	trypan	NNP	O
blue	blue	JJ	O
dye	dye	NN	O
exclusion	exclusion	NN	O
was	be	VBD	O
usually	usually	RB	O
>	>	XX	O
98	98	CD	O
%	%	NN	O
.	.	.	O

Large	large	JJ	O
cultures	culture	NNS	O
of	of	IN	O
MDCK	MDCK	NNP	O
cells	cell	NNS	O
for	for	IN	O
enzyme	enzyme	NNS	O
preparation	preparation	NN	O
were	be	VBD	O
done	do	VBN	O
by	by	IN	O
plating	plate	VBG	O
5âÃâ106	5âãâ106	CD	O
cells	cell	NNS	O
in	in	IN	O
245âmm2	245âmm2	CD	O
dishes	dish	NNS	O
.	.	.	O

Once	once	IN	O
they	-PRON-	PRP	O
reached	reach	VBD	O
nearly	nearly	RB	O
70	70	CD	O
%	%	NN	O
confluence	confluence	NN	O
,	,	,	O
cells	cell	NNS	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
doxycycline	doxycycline	NNP	O
1Â	1â	NN	O
Âµg	Âµg	NNP	O
/	/	SYM	O
mL	mL	NNP	O
,	,	,	O
twoÂ	twoÂ	VBZ	O
days	day	NNS	O
.	.	.	O

After	after	IN	O
twoÂ	twoâ	CD	O
days	day	NNS	O
of	of	IN	O
treatment	treatment	NN	O
,	,	,	O
each	each	DT	O
plate	plate	NN	O
was	be	VBD	O
washed	wash	VBN	O
in	in	IN	O
cold	cold	JJ	O
PBS	PBS	NNP	O
and	and	CC	O
cells	cell	NNS	O
homogenised	homogenise	VBN	O
in	in	IN	O
5âmL	5âml	CD	O
of	of	IN	O
homogenate	homogenate	NNP	O
buffer	buffer	NNP	O
25âmM	25âmm	CD	O
Hepes	Hepes	NNPS	O
pH	pH	NNP	O
8)	8)	CD	O
,	,	,	O
20	20	CD	O
%	%	NN	O
glycerol	glycerol	NN	O
,	,	,	O
135âmM	135âmm	CD	O
NaCl	NaCl	NNP	O
,	,	,	O
5âmM	5âmm	CD	O
ethylenediaminetetraacetic	ethylenediaminetetraacetic	JJ	O
acid	acid	NN	O
EDTA	EDTA	NNP	O
,	,	,	O
1âmM	1âmm	CD	O
ethylene	ethylene	NN	O
glycol	glycol	JJ	O
-	-	:	O
bis(beta	bis(beta	NNP	O
-	-	HYPH	O
aminoethyl	aminoethyl	NNP	O
ether)-N	ether)-n	NN	O
,	,	,	O
N	N	NNP	O
,	,	,	O
Nâ²	Nâ²	NNP	O
,	,	,	O
Nâ²-tetraacetic	nâ²-tetraacetic	JJ	O
acid	acid	NN	O
EGTA	EGTA	NNP	O
,	,	,	O
1âmM	1âmm	CD	O
sodium	sodium	NN	O
orthovanadate	orthovanadate	NN	O
,	,	,	O
and	and	CC	O
protease	protease	NN	O
inhibitor	inhibitor	NN	O
cocktail	cocktail	NN	O
for	for	IN	O
each	each	DT	O
dish	dish	NN	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
collected	collect	VBN	O
with	with	IN	O
a	a	DT	O
rubber	rubber	NN	O
scraper	scraper	NN	O
,	,	,	O
homogenised	homogenise	VBN	O
by	by	IN	O
passing	pass	VBG	O
them	-PRON-	PRP	O
through	through	IN	O
a	a	DT	O
29âG	29âg	CD	O
-	-	HYPH	O
needle	needle	NN	O
syringe	syringe	NN	O
20	20	CD	O
times	time	NNS	O
and	and	CC	O
stored	store	VBN	O
in	in	IN	O
aliquots	aliquot	NNS	O
at	at	IN	O
â80âÂ	â80ââ	NN	O
°	°	,	O
C	C	NNP	O
.	.	.	O

Presence	Presence	NNP	O
of	of	IN	O
OST	OST	NNP	O
-	-	HYPH	O
DGKÎ±	DGKÎ±	NNP	O
was	be	VBD	O
confirmed	confirm	VBN	O
by	by	IN	O
western	western	JJ	O
blotting	blotting	NNP	O
and	and	CC	O
enzyme	enzyme	NNS	O
assay	assay	NNP	O
,	,	,	O
transduced	transduced	NNP	O
DGKÎ±	DGKÎ±	NNP	O
has	have	VBZ	O
an	an	DT	O
activity	activity	NN	O
>	>	NN	O
100	100	CD	O
folds	fold	NNS	O
the	the	DT	O
endogenous	endogenous	JJ	O
DGK.293	dgk.293	NN	O
T	t	NN	O
cells	cell	NNS	O
were	be	VBD	O
transiently	transiently	RB	O
transfected	transfecte	VBN	O
with	with	IN	O
indicated	indicate	VBN	O
DGK	DGK	NNP	O
isoform	isoform	NN	O
plasmid	plasmid	NN	O
DNA	DNA	NNP	O
using	use	VBG	O
Lipofectamine	Lipofectamine	NNP	O
3000	3000	CD	O
,	,	,	O
Invitrogen	Invitrogen	NNP	O
Carlsbad	Carlsbad	NNP	O
,	,	,	O
CA	CA	NNP	O
.	.	.	O

Forty	forty	CD	O
eight	eight	CD	O
hours	hour	NNS	O
after	after	IN	O
transfection	transfection	NN	O
,	,	,	O
cells	cell	NNS	O
were	be	VBD	O
harvested	harvest	VBN	O
and	and	CC	O
homogenised	homogenise	VBN	O
with	with	IN	O
a	a	DT	O
29âG	29âg	CD	O
-	-	HYPH	O
needle	needle	NN	O
using	use	VBG	O
500âÂµL	500ââµl	CD	O
of	of	IN	O
homogenate	homogenate	NN	O
buffer	buffer	NN	O
for	for	IN	O
each	each	DT	O
dish	dish	NN	O
and	and	CC	O
immediately	immediately	RB	O
stored	store	VBD	O
in	in	IN	O
aliquots	aliquot	NNS	O
at	at	IN	O
â80âÂ	â80ââ	NN	O
°	°	,	O
C	C	NNP	O
.	.	.	O

Cells	cell	NNS	O
transfected	transfecte	VBN	O
with	with	IN	O
empty	empty	JJ	O
vector	vector	NN	O
were	be	VBD	O
used	use	VBN	O
as	as	IN	O
controls	control	NNS	O
,	,	,	O
overexpressed	overexpresse	VBN	O
DGK	DGK	NNP	O
has	have	VBZ	O
an	an	DT	O
activity	activity	NN	O
>	>	NFP	O
50	50	CD	O
folds	fold	NNS	O
the	the	DT	O
endogenous	endogenous	JJ	O
.	.	.	O

Essentionally	essentionally	RB	O
,	,	,	O
the	the	DT	O
same	same	JJ	O
procedure	procedure	NN	O
was	be	VBD	O
followed	follow	VBN	O
as	as	IN	O
reported	report	VBN	O
previously	previously	RB	O
in	in	IN	O
Velnati	Velnati	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	.	B
In	in	IN	O
brief	brief	JJ	O
,	,	,	O
DGK	DGK	NNP	O
activity	activity	NN	O
was	be	VBD	O
assayed	assay	VBN	O
by	by	IN	O
measuring	measure	VBG	O
initial	initial	JJ	O
velocities	velocity	NNS	O
5âmin	5âmin	CD	O
at	at	IN	O
27âÂ	27ââ	CD	O
°	°	,	O
C	C	NNP	O
in	in	IN	O
presence	presence	NN	O
of	of	IN	O
saturating	saturate	VBG	O
substrate	substrate	NN	O
concentrations	concentration	NNS	O
.	.	.	O

Reaction	reaction	NN	O
conditions	condition	NNS	O
:	:	:	O
0.9Â	0.9â	NN	O
Âµg	Âµg	NNP	O
/	/	SYM	O
ÂµL	ÂµL	NNP	O
1,2-dioleoyl	1,2-dioleoyl	CD	O
-	-	HYPH	O
sn	sn	JJ	O
-	-	HYPH	O
glycerol	glycerol	JJ	O
,	,	,	O
5âmM	5âmm	CD	O
ATP	ATP	NNP	O
,	,	,	O
0.01Â	0.01Â	NNP	O
ÂµCi	ÂµCi	NNP	O
/	/	SYM	O
ÂµL	ÂµL	NNP	O
Î³32P]-ATP	î³32p]-atp	NN	O
,	,	,	O
1âmM	1âmm	CD	O
sodium	sodium	NN	O
orthovanadate	orthovanadate	NN	O
,	,	,	O
10âmM	10âmm	CD	O
MgCl2	mgcl2	CD	O
,	,	,	O
1.2âmM	1.2âmm	CD	O
EGTA	egta	NN	O
in	in	IN	O
7.5âmM	7.5âmm	CD	O
Hepes	Hepes	NNPS	O
pH	pH	NNP	O
8	8	CD	B
.	.	.	O

Reaction	reaction	NN	O
mixture	mixture	NN	O
is	be	VBZ	O
assembled	assemble	VBN	O
mixing	mix	VBG	O
enzyme	enzyme	NNS	O
24.5Â	24.5â	CD	O
ÂµL	ÂµL	NNP	O
of	of	IN	O
homogenate	homogenate	NNP	O
,	,	,	O
100Ã	100ã	CD	O
inhibitor	inhibitor	NN	O
or	or	CC	O
DMSO	DMSO	NNP	O
0.5Â	0.5â	NN	O
ÂµL	ÂµL	NNP	O
,	,	,	O
5Ã	5ã	CD	O
ATP	atp	NN	O
solution	solution	NN	O
10Â	10Â	NNP	O
ÂµL	ÂµL	NNP	O
of	of	IN	O
25âmM	25âmm	CD	O
ATP	ATP	NNP	O
,	,	,	O
0.05Â	0.05Â	NNP	O
ÂµCi	ÂµCi	NNP	O
/	/	SYM	O
ÂµL	ÂµL	NNP	O
Î³32P]-ATP	Î³32P]-ATP	NNP	O
Perkin	Perkin	NNP	O
-	-	HYPH	O
Elmer	Elmer	NNP	O
,	,	,	O
Milan	Milan	NNP	O
,	,	,	O
Italy	Italy	NNP	O
,	,	,	O
5âmM	5âmm	CD	O
sodium	sodium	NN	O
orthovanadate	orthovanadate	NN	O
,	,	,	O
50âmM	50âmm	CD	O
MgCl2	MgCl2	NNP	O
,	,	,	O
and	and	CC	O
3.3Ã	3.3ã	CD	O
DAG	DAG	NNP	O
solution	solution	NN	O
15Â	15Â	NNP	O
ÂµL	ÂµL	NNP	O
of	of	IN	O
3Â	3Â	NNP	O
Âµg	Âµg	NNP	O
/	/	SYM	O
ÂµL	ÂµL	NNP	O
1,2-dioleoyl	1,2-dioleoyl	CD	O
-	-	HYPH	O
sn	sn	JJ	O
-	-	HYPH	O
glycerol	glycerol	NN	O
resuspended	resuspend	VBN	O
by	by	IN	O
sonication	sonication	NN	O
in	in	IN	O
4âmM	4âmm	CD	O
EGTA	EGTA	NNP	O
in	in	IN	O
25âmM	25âmm	CD	O
Hepes	Hepes	NNPS	O
pH	pH	NNP	O
8)	8)	CD	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
stopped	stop	VBN	O
after	after	IN	O
5âmin	5âmin	CD	O
by	by	IN	O
adding	add	VBG	O
200Â	200â	CD	O
ÂµL	ÂµL	NNP	O
of	of	IN	O
freshly	freshly	RB	O
prepared	prepared	JJ	O
1Â	1â	NN	O
M	M	NNP	O
HCl	HCl	NNP	O
and	and	CC	O
lipid	lipid	NNP	O
was	be	VBD	O
extracted	extract	VBN	O
by	by	IN	O
adding	add	VBG	O
200Â	200â	CD	O
ÂµL	âµl	NN	O
of	of	IN	O
CH3OH	CH3OH	NNP	O
:	:	:	O
CHCl3	CHCl3	NNP	O
1:1	1:1	NNP	O
solution	solution	NN	O
and	and	CC	O
vortexing	vortexe	VBG	O
for	for	IN	O
1âmin	1âmin	CD	O
.	.	.	O

The	the	DT	O
two	two	CD	O
phases	phase	NNS	O
were	be	VBD	O
separated	separate	VBN	O
by	by	IN	O
centrifugation	centrifugation	NN	O
12,000	12,000	CD	O
RCF	rcf	NN	O
for	for	IN	O
2âmin	2âmin	CD	O
.	.	.	O

Twenty	twenty	CD	O
-	-	HYPH	O
five	five	CD	O
microlitres	microlitre	NNS	O
of	of	IN	O
the	the	DT	O
lower	lower	RBR	O
organic	organic	JJ	O
phase	phase	NN	O
was	be	VBD	O
spotted	spot	VBN	O
in	in	IN	O
small	small	JJ	O
drops	drop	NNS	O
on	on	IN	O
silica	silica	NNP	O
TLC	TLC	NNP	O
plates	plate	NNS	O
.	.	.	O

TLC	TLC	NNP	O
was	be	VBD	O
run	run	VBN	O
10âcm	10âcm	CD	O
and	and	CC	O
dried	dry	VBN	O
before	before	IN	O
radioactive	radioactive	JJ	O
signals	signal	NNS	O
were	be	VBD	O
detected	detect	VBN	O
by	by	IN	O
GS-250	GS-250	NNP	O
molecular	molecular	JJ	O
imager	imager	NN	O
and	and	CC	O
was	be	VBD	O
quantified	quantify	VBN	O
by	by	IN	O
quantity	quantity	NN	O
one	one	CD	O
Bio	Bio	NNP	O
-	-	HYPH	O
Rad	Rad	NNP	O
,	,	,	O
Hercules	Hercules	NNP	O
,	,	,	O
CA	CA	NNP	O
software	software	NN	O
assuring	assure	VBG	O
the	the	DT	O
absence	absence	NN	O
of	of	IN	O
saturated	saturate	VBN	O
spots	spot	NNS	O
.	.	.	O

Percentage	percentage	NN	O
residual	residual	JJ	O
activity	activity	NN	O
was	be	VBD	O
calculated	calculate	VBN	O
as	as	IN	O
follows	follow	VBZ	O
:	:	:	O
OST	OST	NNP	O
-	-	HYPH	O
DGKÎ±	DGKÎ±	NNP	O
homogenate	homogenate	VBP	O
with	with	IN	O
inhibitorÂ	inhibitorÂ	NNP	O
âÂ	âÂ	NNP	O
vector	vector	NN	O
homogenate)/(OST	homogenate)/(OST	NNP	O
-	-	HYPH	O
DGKÎ±	DGKÎ±	NNP	O
homogenate	homogenate	VBP	O
with	with	IN	O
DMSOÂ	DMSOÂ	NNP	O
âÂ	âÂ	NNP	O
vector	vector	NN	O
homogenate)Ã100	homogenate)Ã100	NNP	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
experiments	experiment	NNS	O
were	be	VBD	O
performed	perform	VBN	O
in	in	IN	O
triplicate	triplicate	NN	O
using	use	VBG	O
cells	cell	NNS	O
isolated	isolate	VBN	O
from	from	IN	O
each	each	DT	O
single	single	JJ	O
donor	donor	NN	O
.	.	.	O

Monocytes	Monocytes	NNP	O
250,000	250,000	CD	O
cells	cell	NNS	O
/	/	SYM	O
well	well	UH	O
were	be	VBD	O
treated	treat	VBN	O
for	for	IN	O
1âh	1âh	CD	O
with	with	IN	O
the	the	DT	O
indicated	indicate	VBN	O
drugs	drug	NNS	O
10âÂµM	10ââµm	CD	O
with	with	IN	O
or	or	CC	O
without	without	IN	O
serotonin	serotonin	NN	O
1âÂµM	1ââµm	CD	O
.	.	.	O

Then	then	RB	O
,	,	,	O
cells	cell	NNS	O
were	be	VBD	O
stimulated	stimulate	VBN	O
with	with	IN	O
phorbol	phorbol	NNP	O
12-myristate	12-myristate	CD	O
13-acetate	13-acetate	CD	O
PMA	PMA	NNP	O
;	;	:	O
Sigma	Sigma	NNP	O
-	-	HYPH	O
Aldrich	Aldrich	NNP	O
,	,	,	O
Milano	Milano	NNP	O
,	,	,	O
Italy	Italy	NNP	O
1âÂµM	1ââµm	CD	O
for	for	IN	O
30âmin	30âmin	NNP	O
.	.	.	O

PMA	PMA	NNP	O
is	be	VBZ	O
a	a	DT	O
well	well	RB	O
-	-	HYPH	O
known	know	VBN	O
stimulus	stimulus	NN	O
that	that	WDT	O
induces	induce	VBZ	O
a	a	DT	O
strong	strong	JJ	O
and	and	CC	O
significant	significant	JJ	O
respiratory	respiratory	JJ	O
burst	burst	NN	O
via	via	IN	O
PKC	pkc	JJ	O
activation	activation	NN	B
.	.	.	O

Superoxide	superoxide	NN	O
anion	anion	NN	O
production	production	NN	O
was	be	VBD	O
then	then	RB	O
evaluated	evaluate	VBN	O
by	by	IN	O
the	the	DT	O
superoxide	superoxide	NN	O
dismutase	dismutase	NN	O
SOD)-sensitive	SOD)-sensitive	``	O
cytochrome	cytochrome	FW	O
C	c	NN	O
CytC	CytC	NNP	O
reduction	reduction	NN	O
assay	assay	NN	O
and	and	CC	O
expressed	express	VBD	O
as	as	IN	O
nmoles	nmole	NNS	O
CytC	CytC	NNP	O
reduced/106	reduced/106	NNP	O
cells/30âmin	cells/30âmin	NN	O
,	,	,	O
using	use	VBG	O
an	an	DT	O
extinction	extinction	NN	O
coefficient	coefficient	NN	O
of	of	IN	O
21.1âmM.	21.1âmm.	CD	O
To	to	TO	O
avoid	avoid	VB	O
interference	interference	NN	O
with	with	IN	O
spectrophotometrical	spectrophotometrical	JJ	O
recordings	recording	NNS	O
,	,	,	O
cells	cell	NNS	O
were	be	VBD	O
incubated	incubate	VBN	O
with	with	IN	O
RPMI	RPMI	NNP	O
1640	1640	CD	O
without	without	IN	O
phenol	phenol	NNP	O
red	red	NNP	O
,	,	,	O
antibiotics	antibiotic	NNS	O
,	,	,	O
and	and	CC	O
FBS	FBS	NNP	O
.	.	.	O

Activated	activate	VBN	O
human	human	JJ	O
PBLs	pbl	NNS	O
were	be	VBD	O
transfected	transfecte	VBN	O
with	with	IN	O
200âpmol	200âpmol	CD	O
of	of	IN	O
siRNA	siRNA	NNP	O
oligonucleotides	oligonucleotide	NNS	O
specific	specific	JJ	O
for	for	IN	O
the	the	DT	O
target	target	NN	O
protein	protein	NN	O
Stealth	Stealth	NNP	O
Select	Select	NNP	O
siRNA	sirna	NN	O
;	;	:	O
Life	Life	NNP	O
Technologies	Technologies	NNPS	O
,	,	,	O
Carlsbad	Carlsbad	NNP	O
,	,	,	O
CA	CA	NNP	O
or	or	CC	O
a	a	DT	O
non	non	JJ	O
-	-	JJ	O
specific	specific	JJ	O
control	control	NN	O
oligo	oligo	NNS	O
Life	Life	NNP	O
Technologies	Technologies	NNPS	O
,	,	,	O
Carlsbad	Carlsbad	NNP	O
,	,	,	O
CA	CA	NNP	O
.	.	.	O

Transient	transient	JJ	O
transfections	transfection	NNS	O
were	be	VBD	O
performed	perform	VBN	O
using	use	VBG	O
Amaxa	Amaxa	NNP	O
nucleofector	nucleofector	NN	O
kits	kit	NNS	O
for	for	IN	O
human	human	JJ	O
T	t	NN	O
cells	cell	NNS	O
Lonza	Lonza	NNP	O
,	,	,	O
Basel	Basel	NNP	O
,	,	,	O
Switzerland	Switzerland	NNP	O
and	and	CC	O
the	the	DT	O
Amaxa	Amaxa	NNP	O
Nucleofector	Nucleofector	NNP	O
II	II	NNP	O
or	or	CC	O
4D	4d	CD	O
systems	system	NNS	O
programmes	programme	NNS	O
T-20	t-20	CD	O
or	or	CC	O
EI-115	EI-115	NNP	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
cultured	culture	VBN	O
in	in	IN	O
IL-2	IL-2	NNP	O
100âIU	100âiu	CD	O
/	/	SYM	O
mL	ml	NN	O
for	for	IN	O
fourÂ	fourÂ	NNP	O
days	day	NNS	O
to	to	TO	O
allow	allow	VB	O
target	target	NN	O
gene	gene	NN	O
knockdown	knockdown	VBN	O
.	.	.	O

Knockdown	knockdown	JJ	O
efficiency	efficiency	NN	O
was	be	VBD	O
periodically	periodically	RB	O
evaluated	evaluate	VBN	O
by	by	IN	O
Western	western	JJ	O
blotting	blotting	NN	O
.	.	.	O

Non	non	JJ	O
-	-	JJ	O
specific	specific	JJ	O
Stealth	Stealth	NNP	O
RNAi	RNAi	NNS	O
Negative	Negative	NNP	O
Control	Control	NNP	O
Duplexes	Duplexes	NNP	O
12935	12935	CD	O
-	-	SYM	O
300	300	CD	O
,	,	,	O
Life	Life	NNP	O
Technologies	Technologies	NNPS	O
,	,	,	O
Carlsbad	Carlsbad	NNP	O
,	,	,	O
CA	CA	NNP	O
were	be	VBD	O
used	use	VBN	O
as	as	IN	O
a	a	DT	O
negative	negative	JJ	O
control.siRNA	control.sirna	JJ	O
SAP	sap	NN	O
:	:	:	O
sense	sense	NN	O
strand	strand	NNP	O
UGUACUGCCUAUGUGUGCUGUAUCA	UGUACUGCCUAUGUGUGCUGUAUCA	NNP	O
,	,	,	O
antisense	antisense	NN	O
strand	strand	NN	O
UGAUACAGCAGACAUAGGCAGUACA	UGAUACAGCAGACAUAGGCAGUACA	NNP	O
.	.	.	O

To	to	TO	O
test	test	NN	O
restimulation	restimulation	NN	O
induced	induce	VBN	O
cell	cell	NN	O
death	death	NN	O
,	,	,	O
activated	activate	VBN	O
T	t	NN	O
cells	cell	NNS	O
105	105	CD	O
cells	cell	NNS	O
/	/	SYM	O
well	well	UH	O
were	be	VBD	O
plated	plate	VBN	O
in	in	IN	O
triplicate	triplicate	NN	O
in	in	IN	O
96-well	96-well	CD	O
round	round	JJ	O
-	-	HYPH	O
bottom	bottom	NN	O
plate	plate	NN	O
and	and	CC	O
treated	treat	VBN	O
with	with	IN	O
anti	anti	JJ	O
-	-	JJ	O
CD3	cd3	JJ	O
clone	clone	NN	O
OKT3	OKT3	NNP	O
10âng	10âng	CD	O
/	/	SYM	O
mL	mL	NNP	O
in	in	IN	O
RPMI	RPMI	NNP	O
-	-	HYPH	O
GlutaMAX	GlutaMAX	NNS	O
supplemented	supplement	VBN	O
with	with	IN	O
100âIU	100âiu	CD	O
/	/	SYM	O
mL	mL	NNP	O
rhIL-2	rhIL-2	-LRB-	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

In	in	IN	O
these	these	DT	O
assays	assay	NNS	O
,	,	,	O
inhibitors	inhibitor	NNS	O
10âÂµM	10ââµm	CD	O
were	be	VBD	O
added	add	VBN	O
30âmin	30âmin	NN	O
before	before	IN	O
the	the	DT	O
restimulation	restimulation	NN	O
with	with	IN	O
OKT3	OKT3	NNP	O
.	.	.	O

24âh	24âh	CD	O
after	after	IN	O
treatment	treatment	NN	O
,	,	,	O
cells	cell	NNS	O
were	be	VBD	O
stained	stain	VBN	O
with	with	IN	O
20âng	20âng	CD	O
/	/	SYM	O
mL	mL	NNP	O
propidium	propidium	NN	O
iodide	iodide	NN	O
and	and	CC	O
collected	collect	VBN	O
for	for	IN	O
a	a	DT	O
constant	constant	JJ	O
time	time	NN	O
of	of	IN	O
30âs	30âs	CD	O
per	per	IN	O
sample	sample	NN	O
on	on	IN	O
Attune	Attune	NNP	O
Nxt	Nxt	NNP	O
Flow	Flow	NNP	O
Cytometer	Cytometer	NNP	O
Thermo	Thermo	NNP	O
Fisher	Fisher	NNP	O
Scientific	Scientific	NNP	O
,	,	,	O
Waltham	Waltham	NNP	O
,	,	,	O
MA	MA	NNP	O
.	.	.	O

Cell	cell	NN	O
death	death	NN	O
is	be	VBZ	O
expressed	express	VBN	O
as	as	IN	O
%	%	NN	O
cell	cell	NN	O
loss	loss	NN	O
and	and	CC	O
calculated	calculate	VBD	O
as	as	IN	O
:	:	:	O
%	%	NN	O
Â	â	NN	O
cellÂ	cellÂ	NNP	O
loss=(1â(numberÂ	loss=(1â(numberÂ	VBD	O
ofÂ	ofÂ	NNP	O
viableÂ	viableÂ	NNP	O
cellsÂ	cellsÂ	NNP	O
inÂ	inâ	JJ	O
samplenumberÂ	samplenumberâ	FW	O
ofÂ	ofÂ	NNP	O
viableÂ	viableÂ	NNP	O
cellsÂ	cellsÂ	NNP	O
inÂ	inâ	NN	O
control)Ã100)Results	control)ã100)result	NNS	O
were	be	VBD	O
expressed	express	VBN	O
as	as	IN	O
meanâÂ±âstandard	meanââ±âstandard	NN	O
error	error	NN	O
of	of	IN	O
the	the	DT	O
mean	mean	NN	O
SEM	SEM	NNP	O
.	.	.	O

We	-PRON-	PRP	O
always	always	RB	O
compared	compare	VBD	O
controls	control	NNS	O
and	and	CC	O
SAP	sap	NN	O
silenced	silence	VBD	O
lymphocytes	lymphocyte	NNS	O
from	from	IN	O
the	the	DT	O
same	same	JJ	O
donors	donor	NNS	O
as	as	IN	O
there	there	EX	O
is	be	VBZ	O
a	a	DT	O
large	large	JJ	O
individual	individual	JJ	O
variability	variability	NN	O
in	in	IN	O
RICD	RICD	NNP	O
sensitivity	sensitivity	NN	O
.	.	.	O

Cell	cell	NN	O
migration	migration	NN	O
assays	assay	NNS	O
were	be	VBD	O
performed	perform	VBN	O
using	use	VBG	O
the	the	DT	O
Culture	Culture	NNP	O
-	-	HYPH	O
Insert	Insert	NNP	O
2	2	CD	O
well	well	RB	O
in	in	IN	O
Âµ-Dish	Âµ-Dish	NNP	O
ibidi	ibidi	NNP	O
GmbH	GmbH	NNP	O
,	,	,	O
Martinsried	Martinsried	NNP	O
,	,	,	O
Germany	Germany	NNP	O
.	.	.	O

Briefly	briefly	RB	O
,	,	,	O
25,000	25,000	CD	O
MCF7	MCF7	NNP	O
cells	cell	NNS	O
were	be	VBD	O
plated	plate	VBN	O
in	in	IN	O
each	each	DT	O
well	well	NN	O
and	and	CC	O
cultured	culture	VBD	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

The	the	DT	O
day	day	NN	O
after	after	RB	O
,	,	,	O
the	the	DT	O
culture	culture	NN	O
insert	insert	NN	O
was	be	VBD	O
removed	remove	VBN	O
and	and	CC	O
the	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
PBS	PBS	NNP	O
before	before	IN	O
treating	treat	VBG	O
them	-PRON-	PRP	O
with	with	IN	O
respective	respective	JJ	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
10âÂµM	10ââµm	CD	O
or	or	CC	O
DMSO	DMSO	NNP	O
for	for	IN	O
15âh	15âh	CD	O
in	in	IN	O
complete	complete	JJ	O
medium	medium	NN	O
DMEM	DMEM	NNP	O
10	10	CD	O
%	%	NN	O
FBS	fbs	NN	O
+	+	SYM	O
1	1	CD	O
%	%	NN	O
penicillin	penicillin	NN	O
/	/	SYM	O
streptomycin	streptomycin	NN	O
,	,	,	O
while	while	IN	O
medium	medium	NN	O
without	without	IN	O
FBS	FBS	NNP	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
a	a	DT	O
negative	negative	JJ	O
control	control	NN	O
for	for	IN	O
migration	migration	NN	O
.	.	.	O

Phase	phase	NN	O
-	-	HYPH	O
contrast	contrast	NN	O
pictures	picture	NNS	O
were	be	VBD	O
taken	take	VBN	O
immediately	immediately	RB	O
after	after	IN	O
treatment	treatment	NN	O
0âh	0âh	NFP	O
and	and	CC	O
after	after	IN	O
15âh	15âh	CD	O
under	under	IN	O
5Ã	5ã	CD	O
magnification	magnification	NN	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
wound	wind	VBN	O
areas	area	NNS	O
were	be	VBD	O
determined	determine	VBN	O
using	use	VBG	O
ImageJ	ImageJ	NNPS	O
software	software	NN	O
NIH	NIH	NNP	O
,	,	,	O
,	,	,	O
Bethesda	Bethesda	NNP	O
,	,	,	O
MD	MD	NNP	O
.	.	.	O

Wound	Wound	NNP	O
reduction	reduction	NN	O
was	be	VBD	O
calculated	calculate	VBN	O
by	by	IN	O
using	use	VBG	O
the	the	DT	O
following	follow	VBG	O
formula	formula	NN	O
:	:	:	O
wound	wound	NNP	O
area	area	NN	O
at	at	IN	O
15âh	15âh	CD	O
/	/	SYM	O
wound	wind	VBN	O
at	at	IN	O
0âh)Ã100	0âh)ã100	CD	O
,	,	,	O
the	the	DT	O
values	value	NNS	O
obtained	obtain	VBN	O
were	be	VBD	O
expressed	express	VBN	O
as	as	IN	O
the	the	DT	O
percentage	percentage	NN	O
of	of	IN	O
wound	wound	NN	O
area	area	NN	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
initial	initial	JJ	O
area	area	NN	O
.	.	.	O

Data	datum	NNS	O
for	for	IN	O
the	the	DT	O
screen	screen	NN	O
on	on	IN	O
OST	OST	NNP	O
-	-	HYPH	O
DGKÎ±	DGKÎ±	NNP	O
homogenates	homogenate	NNS	O
are	be	VBP	O
the	the	DT	O
mean	mean	NN	O
of	of	IN	O
duplicates	duplicate	NNS	O
.	.	.	O

The	the	DT	O
compounds	compound	NNS	O
showing	show	VBG	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
in	in	IN	O
this	this	DT	O
assay	assay	NN	O
were	be	VBD	O
tested	test	VBN	O
>	>	XX	O
4	4	CD	O
times	time	NNS	O
and	and	CC	O
the	the	DT	O
meanâÂ±âSEM	meanâÂ±âSEM	NNP	O
is	be	VBZ	O
reported	report	VBN	O
.	.	.	O

To	to	TO	O
calculate	calculate	VB	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
active	active	JJ	O
inhibitors	inhibitor	NNS	O
,	,	,	O
the	the	DT	O
inhibitor	inhibitor	NN	O
activity	activity	NN	O
was	be	VBD	O
measured	measure	VBN	O
at	at	RB	O
least	least	RBS	O
three	three	CD	O
times	time	NNS	O
at	at	IN	O
0.1	0.1	CD	O
,	,	,	O
1.0	1.0	CD	O
,	,	,	O
10.0	10.0	CD	O
,	,	,	O
and	and	CC	O
100.0Â	100.0â	CD	O
ÂµM	âµm	NN	O
concentration	concentration	NN	O
.	.	.	O

Data	datum	NNS	O
were	be	VBD	O
analysed	analyse	VBN	O
using	use	VBG	O
inhibitor	inhibitor	NN	O
vs.	vs.	CC	O
normalised	normalised	JJ	O
response	response	NN	O
parameters	parameter	NNS	O
with	with	IN	O
least	least	JJS	O
square	square	JJ	O
ordinary	ordinary	JJ	O
curve	curve	NN	O
fitting	fitting	NN	O
method	method	NN	O
in	in	IN	O
GraphPad	GraphPad	NNP	O
PRISM	prism	IN	O
8.0	8.0	CD	O
software	software	NN	O
GraphPad	GraphPad	NNP	O
Software	Software	NNP	O
,	,	,	O
La	La	NNP	O
Jolla	Jolla	NNP	O
,	,	,	O
CA	CA	NNP	O
mentioning	mention	VBG	O
95	95	CD	O
%	%	NN	O
confidence	confidence	NN	O
interval	interval	NN	O
and	and	CC	O
IC50	IC50	NNP	O
values	value	NNS	O
always	always	RB	O
greater	great	JJR	O
than	than	IN	O
0.0	0.0	CD	O
.	.	.	O

Graph	Graph	NNP	O
shows	show	VBZ	O
the	the	DT	O
meanâÂ±âSEM	meanâÂ±âSEM	NNP	O
of	of	IN	O
inhibitor	inhibitor	NN	O
activity	activity	NN	O
at	at	IN	O
the	the	DT	O
indicated	indicate	VBN	O
concentration	concentration	NN	O
.	.	.	O

In	in	IN	O
all	all	PDT	O
the	the	DT	O
experiments	experiment	NNS	O
,	,	,	O
the	the	DT	O
data	datum	NNS	O
were	be	VBD	O
normalised	normalise	VBN	O
with	with	IN	O
the	the	DT	O
controls	control	NNS	O
.	.	.	O

Evaluation	evaluation	NN	O
of	of	IN	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
assays	assay	NNS	O
across	across	IN	O
multiple	multiple	JJ	O
treatments	treatment	NNS	O
RICD	RICD	NNP	O
,	,	,	O
SOD	SOD	NNP	O
-	-	HYPH	O
sensitive	sensitive	JJ	O
CytC	CytC	NNP	O
reduction	reduction	NN	O
assay	assay	NN	O
,	,	,	O
migration	migration	NN	O
assays	assay	NNS	O
were	be	VBD	O
analysed	analyse	VBN	O
by	by	IN	O
using	use	VBG	O
one	one	CD	O
-	-	HYPH	O
way	way	NN	O
ANOVA	ANOVA	NNP	O
with	with	IN	O
multiple	multiple	JJ	O
comparisons	comparison	NNS	O
correction	correction	NN	O
using	use	VBG	O
GraphPad	GraphPad	NNP	O
PRISM	prism	IN	O
8.0	8.0	CD	O
software	software	NN	O
GraphPad	GraphPad	NNP	O
Software	Software	NNP	O
,	,	,	O
La	La	NNP	O
Jolla	Jolla	NNP	O
,	,	,	O
CA	CA	NNP	O
.	.	.	O

Error	error	NN	O
bars	bar	NNS	O
are	be	VBP	O
described	describe	VBN	O
in	in	IN	O
figure	figure	NN	O
legends	legend	VBZ	O
asâÂ±âSEM	asââ±âsem	RB	O
orâÂ±âSD	orââ±âsd	DT	O
where	where	WRB	O
appropriate	appropriate	JJ	O
.	.	.	O

A	a	DT	O
single	single	JJ	O
,	,	,	O
double	double	JJ	O
,	,	,	O
triple	triple	JJ	O
and	and	CC	O
four	four	CD	O
asterisk	asterisk	NN	O
denotes	denote	VBZ	O
significance	significance	NN	O
of	of	IN	O
a	a	DT	O
p	p	NN	O
value	value	NN	O
â¤0.05	â¤0.05	NNP	O
,	,	,	O
â¤0.01	â¤0.01	NNP	O
,	,	,	O
â¤0.001	â¤0.001	NNP	O
,	,	,	O
and	and	CC	O
â¤0.0001	â¤0.0001	VBP	O
respectively	respectively	RB	O
in	in	IN	O
all	all	DT	O
experiments	experiment	NNS	O
.	.	.	O

A	a	DT	O
representative	representative	JJ	O
3D	3d	NN	O
structure	structure	NN	O
of	of	IN	O
each	each	DT	O
compound	compound	NN	O
was	be	VBD	O
generated	generate	VBN	O
using	use	VBG	O
OMEGA2	OMEGA2	NNP	O
software	software	NN	B
.	.	.	O

The	the	DT	O
generated	generate	VBN	O
file	file	NN	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
generate	generate	VB	O
a	a	DT	O
pharmacophore	pharmacophore	NN	O
model	model	NN	O
with	with	IN	O
the	the	DT	O
Pharmagist	Pharmagist	NNP	O
web	web	NN	O
server	server	NN	O
bioinfo3d.cs.tau.ac.il/PharmaGist/	bioinfo3d.cs.tau.ac.il/pharmagist/	NN	O
)	)	-RRB-	B
.	.	.	O

At	at	IN	O
the	the	DT	O
beginning	beginning	NN	O
,	,	,	O
we	-PRON-	PRP	O
purchased	purchase	VBD	O
14	14	CD	O
analogues	analogue	NNS	O
of	of	IN	O
Amb639752	Amb639752	NNP	O
by	by	IN	O
vendors	vendor	NNS	O
Figure	figure	NN	O
3	3	CD	O
,	,	,	O
while	while	IN	O
one	one	CD	O
analogue	analogue	NN	O
2	2	CD	O
,	,	,	O
being	be	VBG	O
not	not	RB	O
commercially	commercially	RB	O
available	available	JJ	O
,	,	,	O
was	be	VBD	O
synthesised	synthesise	VBN	O
see	see	VB	O
Supplementary	supplementary	JJ	O
material	material	NN	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
compounds	compound	NNS	O
were	be	VBD	O
evaluated	evaluate	VBN	O
for	for	IN	O
their	-PRON-	PRP$	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
on	on	IN	O
DGKÎ±	DGKÎ±	NNP	O
at	at	IN	O
a	a	DT	O
concentration	concentration	NN	O
of	of	IN	O
100âÂµM	100ââµm	CD	O
Table	table	NN	O
1	1	CD	O
.	.	.	O

First	first	RB	O
set	set	NN	O
of	of	IN	O
compounds	compound	NNS	O
tested	test	VBN	O
for	for	IN	O
their	-PRON-	PRP$	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
on	on	IN	O
DGKÎ±.	DGKÎ±.	NNP	O
Inhibitory	Inhibitory	NNP	O
activity	activity	NN	O
on	on	IN	O
DGKÎ±	DGKÎ±	NNP	O
I	i	NN	O
.	.	.	O

Each	each	DT	O
inhibitor	inhibitor	NN	O
was	be	VBD	O
tested	test	VBN	O
in	in	IN	O
duplicate	duplicate	NNP	O
at	at	IN	O
least	least	JJS	O
once	once	RB	O
,	,	,	O
and	and	CC	O
DGKÎ±	DGKÎ±	NNP	O
activity	activity	NN	O
was	be	VBD	O
expressed	express	VBN	O
as	as	IN	O
percentage	percentage	NN	O
of	of	IN	O
residual	residual	JJ	O
DGKÎ±	DGKÎ±	NNP	O
activity	activity	NN	O
compared	compare	VBN	O
to	to	IN	O
DMSO	DMSO	NNP	O
control	control	NN	O
in	in	IN	O
the	the	DT	O
same	same	JJ	O
assay	assay	NN	O
.	.	.	O

Assay	Assay	NNP	O
uses	use	VBZ	O
OST	OST	NNP	O
-	-	HYPH	O
DGKÎ±	DGKÎ±	NNP	O
overexpressing	overexpresse	VBG	O
cell	cell	NN	O
lysates	lysate	NNS	O
in	in	IN	O
presence	presence	NN	O
of	of	IN	O
saturating	saturate	VBG	O
exogenous	exogenous	JJ	O
DAG	DAG	NNP	O
and	and	CC	O
ATP	ATP	NNP	O
.	.	.	O

We	-PRON-	PRP	O
considered	consider	VBD	O
R59022	R59022	NNP	O
commercially	commercially	RB	O
available	available	JJ	O
and	and	CC	O
the	the	DT	O
lead	lead	JJ	O
compound	compound	VBP	O
Amb63975230	Amb63975230	NNP	O
as	as	IN	O
our	-PRON-	PRP$	O
reference	reference	NN	O
molecules	molecule	NNS	O
.	.	.	O

As	as	IN	O
expected	expect	VBN	O
,	,	,	O
our	-PRON-	PRP$	O
reference	reference	NN	O
inhibitors	inhibitor	NNS	O
R59022	R59022	NNP	O
and	and	CC	O
Amb639752	Amb639752	NNP	O
featured	feature	VBD	O
73	73	CD	O
%	%	NN	O
and	and	CC	O
96	96	CD	O
%	%	NN	O
inhibition	inhibition	NN	O
respectively	respectively	RB	O
,	,	,	O
confirming	confirm	VBG	O
the	the	DT	O
quality	quality	NN	O
of	of	IN	O
data	datum	NNS	O
obtained	obtain	VBN	O
.	.	.	O

This	this	DT	O
first	first	JJ	O
screening	screening	NN	O
showed	show	VBD	O
us	-PRON-	PRP	O
how	how	WRB	O
Amb639752	Amb639752	NNP	O
exhibits	exhibit	VBZ	O
a	a	DT	O
rigid	rigid	JJ	O
structure	structure	NN	O
activity	activity	NN	O
relationship	relationship	NN	O
.	.	.	O

Indeed	indeed	RB	O
,	,	,	O
both	both	CC	O
the	the	DT	O
methyl	methyl	NN	O
groups	group	NNS	O
on	on	IN	O
the	the	DT	O
2,6	2,6	CD	O
position	position	NN	O
of	of	IN	O
indole	indole	NNP	O
are	be	VBP	O
mandatory	mandatory	JJ	O
,	,	,	O
the	the	DT	O
NH	NH	NNP	O
indole	indole	NN	O
can	can	MD	O
not	not	RB	O
be	be	VB	O
alkylated	alkylate	VBN	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
ramifications	ramification	NNS	O
on	on	IN	O
the	the	DT	O
alkyl	alkyl	NN	O
chain	chain	NN	O
are	be	VBP	O
detrimental	detrimental	JJ	O
.	.	.	O

We	-PRON-	PRP	O
then	then	RB	O
focussed	focusse	VBD	O
our	-PRON-	PRP$	O
attention	attention	NN	O
on	on	IN	O
furan	furan	NNP	O
ring	ring	NN	O
knowing	know	VBG	O
its	-PRON-	PRP$	O
intrinsic	intrinsic	JJ	O
toxicity	toxicity	NN	O
via	via	IN	O
metabolic	metabolic	JJ	O
activation	activation	NN	B
.	.	.	O

Unfortunately	unfortunately	RB	O
,	,	,	O
there	there	EX	O
were	be	VBD	O
no	no	DT	O
analogues	analogue	NNS	O
available	available	JJ	O
by	by	IN	O
vendors	vendor	NNS	O
.	.	.	O

Our	-PRON-	PRP$	O
first	first	JJ	O
goal	goal	NN	O
was	be	VBD	O
to	to	TO	O
replace	replace	VB	O
the	the	DT	O
furan	furan	NNP	O
moiety	moiety	NNP	O
with	with	IN	O
the	the	DT	O
phenyl	phenyl	NNP	O
ring	ring	NN	O
,	,	,	O
investigating	investigate	VBG	O
two	two	CD	O
different	different	JJ	O
synthetic	synthetic	JJ	O
pathways	pathway	NNS	O
.	.	.	O

In	in	IN	O
the	the	DT	O
first	first	JJ	O
one	one	CD	O
,	,	,	O
the	the	DT	O
commercially	commercially	RB	O
available	available	JJ	O
2,6-dimethyl-1H	2,6-dimethyl-1h	CD	O
-	-	HYPH	O
indole	indole	NNP	O
3	3	CD	O
was	be	VBD	O
acylated	acylate	VBN	O
with	with	IN	O
2-chloroacetyl	2-chloroacetyl	CD	O
chloride	chloride	NN	O
4	4	CD	O
,	,	,	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
DBU	DBU	NNP	O
in	in	IN	O
dichloroethane	dichloroethane	JJ	B
to	to	TO	O
give	give	VB	O
the	the	DT	O
derivative	derivative	JJ	O
5	5	CD	O
90	90	CD	O
%	%	NN	O
yield	yield	NN	O
.	.	.	O

Then	then	RB	O
,	,	,	O
the	the	DT	O
acylated	acylated	JJ	O
compound	compound	NN	O
5	5	CD	O
was	be	VBD	O
reacted	react	VBN	O
with	with	IN	O
N	N	NNP	O
-	-	HYPH	O
Boc	boc	NN	O
piperazine	piperazine	NN	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
potassium	potassium	NN	O
carbonate	carbonate	NN	O
and	and	CC	O
potassium	potassium	NN	O
iodide	iodide	NN	O
to	to	TO	O
afford	afford	VB	O
the	the	DT	O
piperazinic	piperazinic	JJ	O
derivative	derivative	JJ	O
6	6	CD	O
in	in	IN	O
63	63	CD	O
%	%	NN	O
yield	yield	NN	O
.	.	.	O

Boc	boc	NN	O
deprotection	deprotection	NN	O
with	with	IN	O
trifluoroacetic	trifluoroacetic	JJ	O
acid	acid	NN	O
,	,	,	O
followed	follow	VBN	O
by	by	IN	O
coupling	couple	VBG	O
with	with	IN	O
benzoic	benzoic	JJ	O
acid	acid	NN	O
using	use	VBG	O
the	the	DT	O
condensing	condense	VBG	O
agent	agent	NN	O
EDCI	EDCI	NNP	O
afforded	afford	VBD	O
the	the	DT	O
final	final	JJ	O
compound	compound	NN	O
8	8	CD	O
Scheme	scheme	NN	O
1	1	CD	O
.	.	.	O

The	the	DT	O
first	first	JJ	O
synthetic	synthetic	JJ	O
route	route	NN	O
for	for	IN	O
the	the	DT	O
compound	compound	NN	O
8	8	CD	O
.	.	.	O

In	in	IN	O
the	the	DT	O
second	second	JJ	O
synthetic	synthetic	JJ	O
strategy	strategy	NN	O
,	,	,	O
we	-PRON-	PRP	O
initially	initially	RB	O
coupled	couple	VBD	O
the	the	DT	O
benzoic	benzoic	JJ	O
acid	acid	NN	O
with	with	IN	O
N	N	NNP	O
-	-	HYPH	O
Boc	boc	NN	O
piperazine	piperazine	NN	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
EDCI	EDCI	NNP	O
to	to	TO	O
give	give	VB	O
piperazinic	piperazinic	JJ	O
derivative	derivative	JJ	O
9	9	CD	O
in	in	IN	O
49	49	CD	O
%	%	NN	O
yield	yield	NN	O
.	.	.	O

Boc	boc	NN	O
deprotection	deprotection	NN	O
gave	give	VBD	O
in	in	IN	O
quantitative	quantitative	JJ	O
yield	yield	VB	O
the	the	DT	O
compound	compound	NN	O
10	10	CD	O
.	.	.	O

Due	due	IN	O
to	to	IN	O
its	-PRON-	PRP$	O
high	high	JJ	O
aqueous	aqueous	JJ	O
solubility	solubility	NN	O
,	,	,	O
solvent	solvent	NN	O
was	be	VBD	O
evaporated	evaporate	VBN	O
and	and	CC	O
the	the	DT	O
crude	crude	NN	O
as	as	IN	O
trifluoroacetate	trifluoroacetate	NN	O
salt	salt	NN	O
was	be	VBD	O
directly	directly	RB	O
used	use	VBN	O
for	for	IN	O
the	the	DT	O
next	next	JJ	O
step	step	NN	O
,	,	,	O
where	where	WRB	O
it	-PRON-	PRP	O
was	be	VBD	O
reacted	react	VBN	O
with	with	IN	O
the	the	DT	O
acylated	acylate	VBN	O
indole	indole	NN	O
5	5	CD	O
to	to	TO	O
give	give	VB	O
the	the	DT	O
final	final	JJ	O
compound	compound	NN	O
8	8	CD	O
in	in	IN	O
25	25	CD	O
%	%	NN	O
yield	yield	NN	O
Scheme	scheme	NN	O
2	2	CD	O
see	see	VB	O
Supplementary	supplementary	JJ	O
material	material	NN	O
for	for	IN	O
full	full	JJ	O
synthetic	synthetic	JJ	O
details	detail	NNS	O
.	.	.	O

The	the	DT	O
second	second	JJ	O
synthetic	synthetic	JJ	O
route	route	NN	O
for	for	IN	O
the	the	DT	O
compound	compound	NN	O
8	8	CD	O
.	.	.	O

Overall	overall	JJ	O
yield	yield	NN	O
calculation	calculation	NN	O
was	be	VBD	O
11	11	CD	O
%	%	NN	O
for	for	IN	O
both	both	DT	O
strategies	strategy	NNS	O
,	,	,	O
but	but	CC	O
with	with	IN	O
the	the	DT	O
first	first	JJ	O
route	route	NN	O
it	-PRON-	PRP	O
was	be	VBD	O
possible	possible	JJ	O
to	to	TO	O
use	use	VB	O
a	a	DT	O
common	common	JJ	O
synthetic	synthetic	JJ	O
intermediate	intermediate	NN	O
7	7	CD	O
which	which	WDT	O
can	can	MD	O
be	be	VB	O
coupled	couple	VBN	O
with	with	IN	O
different	different	JJ	O
carboxylic	carboxylic	JJ	O
acids	acid	NNS	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
the	the	DT	O
second	second	JJ	O
route	route	NN	O
requires	require	VBZ	O
more	more	JJR	O
purification	purification	NN	O
steps	step	NNS	O
.	.	.	O

For	for	IN	O
this	this	DT	O
reason	reason	NN	O
,	,	,	O
we	-PRON-	PRP	O
applied	apply	VBD	O
the	the	DT	O
first	first	JJ	O
route	route	NN	O
and	and	CC	O
coupled	couple	VBD	O
the	the	DT	O
advanced	advanced	JJ	O
intermediate	intermediate	JJ	O
7	7	CD	O
with	with	IN	O
12	12	CD	O
different	different	JJ	O
carboxylic	carboxylic	JJ	O
acids	acid	NNS	O
Figure	figure	NN	O
4	4	CD	O
to	to	TO	O
afford	afford	VB	O
compounds	compound	NNS	O
11â22	11â22	.	O
Figure	figure	NN	O
5	5	CD	O
.	.	.	O

Carboxylic	carboxylic	JJ	O
acids	acid	NNS	O
used	use	VBD	O
.	.	.	O

Putative	putative	JJ	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
synthesised	synthesise	VBD	O
.	.	.	O

In	in	IN	O
brackets	bracket	NNS	O
the	the	DT	O
yield	yield	NN	O
of	of	IN	O
the	the	DT	O
coupling	couple	VBG	O
reaction	reaction	NN	O
with	with	IN	O
the	the	DT	O
common	common	JJ	O
intermediate	intermediate	JJ	O
7	7	CD	O
.	.	.	O

All	all	PDT	O
those	those	DT	O
molecules	molecule	NNS	O
were	be	VBD	O
dissolved	dissolve	VBN	O
in	in	IN	O
DMSO	DMSO	NNP	O
and	and	CC	O
tested	test	VBN	O
at	at	IN	O
a	a	DT	O
concentration	concentration	NN	O
of	of	IN	O
100âÂµM	100ââµm	CD	O
for	for	IN	O
the	the	DT	O
ability	ability	NN	O
to	to	TO	O
inhibit	inhibit	VB	O
DGKÎ±	DGKÎ±	NNP	O
using	use	VBG	O
equal	equal	JJ	O
amounts	amount	NNS	O
of	of	IN	O
DMSO	DMSO	NNP	O
as	as	IN	O
control	control	NN	O
.	.	.	O

We	-PRON-	PRP	O
identified	identify	VBD	O
eight	eight	CD	O
compounds	compound	NNS	O
capable	capable	JJ	O
of	of	IN	O
reducing	reduce	VBG	O
OST	OST	NNP	O
-	-	HYPH	O
DGKÎ±	DGKÎ±	NNP	O
activity	activity	NN	O
similar	similar	JJ	O
or	or	CC	O
superior	superior	JJ	O
to	to	IN	O
R59022	R59022	NNP	O
Table	table	NN	O
2	2	CD	O
.	.	.	O

Inhibitory	inhibitory	NN	O
activity	activity	NN	O
on	on	IN	O
DGKÎ±	DGKÎ±	NNP	O
II	II	NNP	O
.	.	.	O

To	to	TO	O
measure	measure	VB	O
the	the	DT	O
inhibitor	inhibitor	NN	O
potency	potency	NN	O
,	,	,	O
we	-PRON-	PRP	O
determined	determine	VBD	O
the	the	DT	O
IC50	IC50	NNP	O
values	value	NNS	O
for	for	IN	O
the	the	DT	O
compounds	compound	NNS	O
that	that	WDT	O
resulted	result	VBD	O
active	active	JJ	O
when	when	WRB	O
tested	test	VBN	O
at	at	IN	O
100âÂµM	100ââµm	CD	O
by	by	IN	O
measuring	measure	VBG	O
the	the	DT	O
residual	residual	JJ	O
OST	OST	NNP	O
-	-	HYPH	O
DGKÎ±	DGKÎ±	NNP	O
activity	activity	NN	O
over	over	IN	O
a	a	DT	O
dose	dose	JJ	O
range	range	NN	O
of	of	IN	O
inhibitor	inhibitor	NN	O
concentrations	concentration	NNS	O
0.1âÂµM	0.1ââµm	CD	O
,	,	,	O
1.0âÂµM	1.0ââµm	CD	O
,	,	,	O
10.0âÂµM	10.0ââµm	CD	O
,	,	,	O
and	and	CC	O
100.0âÂµM	100.0ââµm	CD	O
.	.	.	O

For	for	IN	O
R59022	R59022	NNP	O
and	and	CC	O
Amb639752	Amb639752	NNP	O
,	,	,	O
we	-PRON-	PRP	O
measured	measure	VBD	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
15.2âÂ±â5.8âÂµM	15.2ââ±â5.8ââµm	CD	O
and	and	CC	O
6.9âÂ±â3.0âÂµM	6.9ââ±â3.0ââµm	CD	O
respectively	respectively	RB	O
which	which	WDT	O
were	be	VBD	O
comparable	comparable	JJ	O
to	to	IN	O
previous	previous	JJ	O
reports	report	NNS	O
using	use	VBG	O
similar	similar	JJ	O
assay	assay	NN	O
conditions	condition	NNS	B
.	.	.	O

Considering	consider	VBG	O
those	those	DT	O
two	two	CD	O
as	as	IN	O
reference	reference	NN	O
/	/	SYM	O
template	template	NN	O
compounds	compound	NNS	O
,	,	,	O
we	-PRON-	PRP	O
measured	measure	VBD	O
the	the	DT	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
8	8	CD	O
,	,	,	O
11	11	CD	O
,	,	,	O
12	12	CD	O
,	,	,	O
13	13	CD	O
,	,	,	O
14	14	CD	O
,	,	,	O
16	16	CD	O
,	,	,	O
19	19	CD	O
,	,	,	O
and	and	CC	O
20	20	CD	O
as	as	IN	O
3.2âÂ±â1.0	3.2ââ±â1.0	CD	O
,	,	,	O
1.6âÂ±â0.4	1.6ââ±â0.4	CD	O
,	,	,	O
3.6âÂ±â1.2	3.6ââ±â1.2	CD	O
,	,	,	O
6.9âÂ±â2.3	6.9ââ±â2.3	CD	O
,	,	,	O
3.0âÂ±â1.0	3.0âÂ±â1.0	NNP	O
,	,	,	O
32.8âÂ±â11.5	32.8âÂ±â11.5	NNP	O
,	,	,	O
49.7âÂ±â31.7	49.7ââ±â31.7	CD	O
,	,	,	O
and	and	CC	O
1.8âÂ±â0.4âÂµM	1.8ââ±â0.4ââµm	CD	O
,	,	,	O
respectively	respectively	RB	O
,	,	,	O
signifying	signify	VBG	O
that	that	IN	O
their	-PRON-	PRP$	O
activity	activity	NN	O
is	be	VBZ	O
equal	equal	JJ	O
or	or	CC	O
superior	superior	JJ	O
to	to	IN	O
the	the	DT	O
template	template	NN	O
compounds	compound	NNS	O
Figure	Figure	NNP	O
6	6	CD	O
.	.	.	O

Doseâresponse	doseâresponse	NN	O
curves	curve	NNS	O
for	for	IN	O
novel	novel	NN	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

Doseâresponse	doseâresponse	NN	O
of	of	IN	O
the	the	DT	O
most	most	RBS	O
active	active	JJ	O
compounds	compound	NNS	O
along	along	IN	O
with	with	IN	O
their	-PRON-	PRP$	O
IC50	IC50	NNP	O
values	value	NNS	O
.	.	.	O

Data	datum	NNS	O
from	from	IN	O
at	at	RB	O
least	least	RBS	O
three	three	CD	O
independent	independent	JJ	O
experiments	experiment	NNS	O
performed	perform	VBN	O
in	in	IN	O
triplicate	triplicate	NN	O
.	.	.	O

Due	due	IN	O
to	to	IN	O
their	-PRON-	PRP$	O
higher	high	JJR	O
IC50	IC50	NNP	O
values	value	NNS	O
,	,	,	O
we	-PRON-	PRP	O
thus	thus	RB	O
decided	decide	VBD	O
to	to	TO	O
exclude	exclude	VB	O
16	16	CD	O

and	and	CC	O
19	19	CD	O
for	for	IN	O
further	further	JJ	O
experiments	experiment	NNS	O
.	.	.	O

In	in	IN	O
summary	summary	NN	O
,	,	,	O
we	-PRON-	PRP	O
recognised	recognise	VBD	O
six	six	CD	O
compounds	compound	NNS	O
with	with	IN	O
equal	equal	JJ	O
or	or	CC	O
superior	superior	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
compared	compare	VBN	O
to	to	IN	O
commercially	commercially	RB	O
available	available	JJ	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

To	to	TO	O
check	check	VB	O
the	the	DT	O
isoform	isoform	JJ	O
specificity	specificity	NN	O
of	of	IN	O
those	those	DT	O
active	active	JJ	O
molecules	molecule	NNS	O
,	,	,	O
we	-PRON-	PRP	O
tested	test	VBD	O
them	-PRON-	PRP	O
,	,	,	O
along	along	IN	O
with	with	IN	O
Amb639752	Amb639752	NNP	O
,	,	,	O
for	for	IN	O
their	-PRON-	PRP$	O
ability	ability	NN	O
to	to	TO	O
inhibit	inhibit	VB	O
DGKÎ±	DGKÎ±	NNP	O
,	,	,	O
DGKÎ¶	DGKÎ¶	NNP	O
the	the	DT	O
other	other	JJ	O
major	major	JJ	O
DGK	DGK	NNP	O
isoform	isoform	NN	O
expressed	express	VBN	O
in	in	IN	O
lymphocytes	lymphocyte	NNS	O
,	,	,	O
and	and	CC	O
the	the	DT	O
more	more	RBR	O
distantly	distantly	RB	O
related	related	JJ	O
and	and	CC	O
widely	widely	RB	O
expressed	express	VBN	O
DGKÎ¸.	DGKÎ¸.	NNP	O
At	at	IN	O
the	the	DT	O
highest	high	JJS	O
concentration	concentration	NN	O
of	of	IN	O
100Â	100Â	NNP	O
ÂµM	ÂµM	NNP	O
,	,	,	O
all	all	PDT	O
those	those	DT	O
molecules	molecule	NNS	O
resulted	result	VBD	O
in	in	IN	O
highly	highly	RB	O
specific	specific	JJ	O
against	against	IN	O
DGKÎ±	DGKÎ±	NNP	O
as	as	IN	O
like	like	IN	O
their	-PRON-	PRP$	O
parent	parent	NN	O
molecule	molecule	NN	O
,	,	,	O
Amb639752	Amb639752	NNPS	O
by	by	IN	O
completely	completely	RB	O
inhibit	inhibit	VB	O
DGKÎ±	DGKÎ±	NNP	O
whereas	whereas	IN	O
they	-PRON-	PRP	O
do	do	VBP	O
not	not	RB	O
have	have	VB	O
significant	significant	JJ	O
effects	effect	NNS	O
on	on	IN	O
DGKÎ¶	DGKÎ¶	NNP	O
and	and	CC	O
DGKÎ¸	dgkî¸	VB	O
apart	apart	RB	O
from	from	IN	O
20	20	CD	O
which	which	WDT	O
,	,	,	O
at	at	IN	O
the	the	DT	O
contrary	contrary	NN	O
,	,	,	O
acts	act	VBZ	O
as	as	IN	O
an	an	DT	O
activator	activator	NN	O
of	of	IN	O
DGKÎ¸	dgkî¸	JJ	O
Figure	Figure	NNP	O
7	7	CD	O
.	.	.	O

Isoform	isoform	NN	O
specificity	specificity	NN	O
of	of	IN	O
novel	novel	NN	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

293	293	CD	O
T	t	NN	O
cells	cell	NNS	O
were	be	VBD	O
transfected	transfecte	VBN	O
with	with	IN	O
different	different	JJ	O
DGK	DGK	NNP	O
isoforms	isoform	NNS	O
A	a	NN	O
â	â	NNP	O
DGKÎ±	DGKÎ±	NNP	O
,	,	,	O
B	B	NNP	O
â	â	NNP	O
DGKÎ¶	DGKÎ¶	NNPS	O
,	,	,	O
C	C	NNP	O
â	â	NNP	O
DGKÎ¸	dgkî¸	NN	O
,	,	,	O
respectively	respectively	RB	O
or	or	CC	O
empty	empty	JJ	O
vectors	vector	NNS	O
and	and	CC	O
homogenised	homogenise	VBD	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
molecules	molecule	NNS	O
were	be	VBD	O
tested	test	VBN	O
at	at	IN	O
100âÎ¼M	100âî¼m	CD	O
for	for	IN	O
their	-PRON-	PRP$	O
capacity	capacity	NN	O
to	to	TO	O
inhibit	inhibit	VB	O
the	the	DT	O
DGK	DGK	NNP	O
activity	activity	NN	O
of	of	IN	O
the	the	DT	O
different	different	JJ	O
isoform	isoform	NN	O
homogenates	homogenate	NNS	O
.	.	.	O

Data	datum	NNS	O
are	be	VBP	O
meansâÂ±âSEM	meansââ±âsem	RB	O
of	of	IN	O
at	at	RB	O
least	least	RBS	O
three	three	CD	O
independent	independent	JJ	O
experiments	experiment	NNS	O
performed	perform	VBN	O
in	in	IN	O
triplicate	triplicate	NN	O
.	.	.	O

R59022	R59022	NNP	O
,	,	,	O
R59949	R59949	NNP	O
,	,	,	O
and	and	CC	O
ritanserin	ritanserin	VB	O
feature	feature	NN	O
a	a	DT	O
dual	dual	JJ	O
activity	activity	NN	O
as	as	IN	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
and	and	CC	O
serotonin	serotonin	JJ	O
receptor	receptor	NN	O
antagonists	antagonist	NNS	B
.	.	.	O

Conversely	conversely	RB	O
,	,	,	O
Amb639752	Amb639752	NNP	O
was	be	VBD	O
reported	report	VBN	O
as	as	IN	O
a	a	DT	O
selective	selective	NN	O
DGKÎ±	DGKÎ±	NNP	O
inhibitor	inhibitor	NN	O
which	which	WDT	O
has	have	VBZ	O
no	no	DT	O
effects	effect	NNS	O
on	on	IN	O
serotonin	serotonin	JJ	O
activity	activity	NN	B
.	.	.	O

Thus	thus	RB	O
,	,	,	O
we	-PRON-	PRP	O
investigated	investigate	VBD	O
whether	whether	IN	O
the	the	DT	O
active	active	JJ	O
molecules	molecule	NNS	O
identified	identify	VBN	O
affect	affect	NN	O
serotonin	serotonin	NN	O
signalling	signalling	NN	O
.	.	.	O

To	to	IN	O
this	this	DT	O
purpose	purpose	NN	O
,	,	,	O
we	-PRON-	PRP	O
measured	measure	VBD	O
the	the	DT	O
effect	effect	NN	O
of	of	IN	O
serotonin	serotonin	NN	O
on	on	IN	O
PMA	PMA	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
oxidative	oxidative	JJ	O
burst	burst	NN	O
in	in	IN	O
human	human	JJ	O
monocytes	monocyte	NNS	O
.	.	.	O

As	as	IN	O
previously	previously	RB	O
shown	show	VBN	O
,	,	,	O
1âÂµM	1ââµm	CD	O
serotonin	serotonin	NNP	O
reverses	reverse	VBZ	O
the	the	DT	O
oxidative	oxidative	JJ	O
burst	burst	NN	O
to	to	TO	O
control	control	VB	O
values	value	NNS	B
.	.	.	O

Known	know	VBN	O
serotonin	serotonin	JJ	O
receptor	receptor	NN	O
antagonists	antagonist	NNS	O
ritanserin	ritanserin	NNP	O
and	and	CC	O
ketanserin	ketanserin	NNP	O
10âÂµM	10âÂµM	NNP	O
impaired	impair	VBN	O
serotonin	serotonin	JJ	O
action	action	NN	O
,	,	,	O
while	while	IN	O
pure	pure	JJ	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
such	such	JJ	O
as	as	IN	O
Amb639752	Amb639752	NNP	O
had	have	VBD	O
no	no	DT	O
effect	effect	NN	O
Figure	figure	NN	O
8)	8)	CD	O
.	.	.	O

These	these	DT	O
data	datum	NNS	O
indicate	indicate	VBP	O
that	that	IN	O
this	this	DT	O
assay	assay	NN	O
is	be	VBZ	O
sensitive	sensitive	JJ	O
to	to	IN	O
perturbations	perturbation	NNS	O
in	in	IN	O
serotonin	serotonin	NN	O
signalling	signal	VBG	O
independently	independently	RB	O
of	of	IN	O
activity	activity	NN	O
against	against	IN	O
DGKÎ±.	DGKÎ±.	NNP	O
Interestingly	interestingly	RB	O
,	,	,	O
as	as	IN	O
like	like	IN	O
Amb639752	Amb639752	NNP	O
,	,	,	O
all	all	PDT	O
the	the	DT	O
newly	newly	RB	O
synthesised	synthesise	VBN	O
active	active	JJ	O
molecules	molecule	NNS	O
did	do	VBD	O
not	not	RB	O
affect	affect	VB	O
serotonin	serotonin	JJ	O
action	action	NN	O
Figure	figure	NN	O
8)	8)	CD	O
,	,	,	O
indicating	indicate	VBG	O
that	that	IN	O
all	all	PDT	O
those	those	DT	O
molecules	molecule	NNS	O
are	be	VBP	O
not	not	RB	O
serotonin	serotonin	JJ	O
receptor	receptor	NN	O
antagonists	antagonist	NNS	O
.	.	.	O

Novel	Novel	NNP	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
do	do	VBP	O
not	not	RB	O
affect	affect	VB	O
serotonin	serotonin	JJ	O
signalling	signalling	NN	O
.	.	.	O

Human	human	JJ	O
monocytes	monocyte	NNS	O
were	be	VBD	O
pre	pre	VBN	O
-	-	VBN	O
incubated	incubate	VBN	O
for	for	IN	O
1âh	1âh	CD	O
with	with	IN	O
the	the	DT	O
indicated	indicate	VBN	O
drugs	drug	NNS	O
in	in	IN	O
absence	absence	NN	O
or	or	CC	O
presence	presence	NN	O
of	of	IN	O
serotonin	serotonin	NN	O
and	and	CC	O
then	then	RB	O
stimulated	stimulate	VBD	O
with	with	IN	O
PMA	PMA	NNP	O
1Â	1â	NN	O
ÂµM	ÂµM	NNP	O
for	for	IN	O
30âmin	30âmin	NNP	O
â	â	NNP	O
control	control	VB	O
unstimulated	unstimulated	JJ	O
cells	cell	NNS	O
,	,	,	O
PMA	PMA	NNP	O
stimulated	stimulate	VBD	O
cells	cell	NNS	O
,	,	,	O
â	â	NNP	O
PMA	PMA	NNP	O
and	and	CC	O
serotonin	serotonin	NN	O
stimulated	stimulate	VBN	O
cells	cell	NNS	O
.	.	.	O

Results	result	NNS	O
are	be	VBP	O
expressed	express	VBN	O
as	as	IN	O
nÂ	nÂ	NNP	O
moles	mole	NNS	O
of	of	IN	O
reduced	reduce	VBN	O
cytochrome	cytochrome	DT	O
C/106	C/106	NNS	O
cells	cell	NNS	O
.	.	.	O

Data	datum	NNS	O
are	be	VBP	O
meansâÂ±âSEM	meansââ±âsem	RB	O
of	of	IN	O
10	10	CD	O

independent	independent	JJ	O
experiments	experiment	NNS	O
performed	perform	VBN	O
in	in	IN	O
triplicate	triplicate	NN	O
.	.	.	O

Ruffo	Ruffo	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

demonstrated	demonstrate	VBD	O
that	that	IN	O
the	the	DT	O
defective	defective	JJ	O
RICD	RICD	NNP	O
observed	observe	VBN	O
in	in	IN	O
T	T	NNP	O
cells	cell	NNS	O
from	from	IN	O
XLP-1	XLP-1	NNP	O
patients	patient	NNS	O
was	be	VBD	O
rescued	rescue	VBN	O
by	by	IN	O
silencing	silence	VBG	O
DGKÎ±	DGKÎ±	NNP	O
expression	expression	NN	O
or	or	CC	O
by	by	IN	O
pre	pre	JJ	O
-	-	NN	O
treatment	treatment	NN	O
with	with	IN	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
R59949	R59949	NNP	O

or	or	CC	O
R59022	R59022	NNP	B
.	.	.	O

Interestingly	interestingly	RB	O
,	,	,	O
R59022	R59022	NNP	O

also	also	RB	O
showed	show	VBD	O
beneficial	beneficial	JJ	O
effects	effect	NNS	O
in	in	IN	O
an	an	DT	O
inÂ	inÂ	NNP	O
vivo	vivo	NN	O
model	model	NN	O
of	of	IN	O
XLP-1	XLP-1	NNP	O
,	,	,	O
but	but	CC	O
due	due	IN	O
to	to	IN	O
its	-PRON-	PRP$	O
poor	poor	JJ	O
pharmacological	pharmacological	JJ	O
proprieties	propriety	NNS	O
,	,	,	O
its	-PRON-	PRP$	O
use	use	NN	O
in	in	IN	O
human	human	JJ	O
patients	patient	NNS	O
results	result	NNS	O
unlikely	unlikely	JJ	O
.	.	.	O

We	-PRON-	PRP	O
therefore	therefore	RB	O
tested	test	VBD	O
the	the	DT	O
effect	effect	NN	O
all	all	PDT	O
those	those	DT	O
active	active	JJ	O
molecules	molecule	NNS	O
along	along	IN	O
with	with	IN	O
Amb639752	Amb639752	NNP	O
on	on	IN	O
RICD	RICD	NNP	O
sensitivity	sensitivity	NN	O
of	of	IN	O
SAP	sap	NN	O
-	-	HYPH	O
deficient	deficient	JJ	O
T	t	NN	O
cells	cell	NNS	O
.	.	.	O

As	as	IN	O
additional	additional	JJ	O
controls	control	NNS	O
,	,	,	O
we	-PRON-	PRP	O
also	also	RB	O
included	include	VBD	O
ritanserin	ritanserin	NNP	O
and	and	CC	O
ketanserin	ketanserin	NNP	O
to	to	TO	O
evaluate	evaluate	VB	O
the	the	DT	O
contribution	contribution	NN	O
of	of	IN	O
serotonin	serotonin	JJ	O
antagonism	antagonism	NN	O
to	to	IN	O
the	the	DT	O
effects	effect	NNS	O
observed	observe	VBN	O
.	.	.	O

To	to	TO	O
evaluate	evaluate	VB	O
inhibitor	inhibitor	NN	O
efficacy	efficacy	NN	O
in	in	IN	O
physiological	physiological	JJ	O
context	context	NN	O
,	,	,	O
we	-PRON-	PRP	O
modelled	model	VBD	O
XLP-1	XLP-1	NNP	O
by	by	IN	O
silencing	silence	VBG	O
SAP	sap	NN	O
in	in	IN	O
primary	primary	JJ	O
peripheral	peripheral	JJ	O
blood	blood	NN	O
T	t	NN	O
lymphocytes	lymphocyte	VBZ	O
PBLs	pbl	NNS	O
and	and	CC	O
restimulating	restimulate	VBG	O
them	-PRON-	PRP	O
with	with	IN	O
anti	anti	JJ	O
-	-	JJ	O
CD3	cd3	JJ	O

antibody	antibody	NN	O
OKT3	OKT3	NNP	O
10âng	10âng	CD	O
/	/	SYM	O
mL	mL	NNP	O
,	,	,	O
24âh	24âh	CD	O
.	.	.	O

We	-PRON-	PRP	O
pre	pre	VBP	O
-	-	VBD	O
treated	treat	VBD	O
the	the	DT	O
cells	cell	NNS	O
with	with	IN	O
the	the	DT	O
indicated	indicate	VBN	O
inhibitors	inhibitor	NNS	O
for	for	IN	O
30âmin	30âmin	NN	O
at	at	IN	O
a	a	DT	O
concentration	concentration	NN	O
of	of	IN	O
10âÂµM	10ââµm	CD	B
.	.	.	O

In	in	IN	O
control	control	NN	O
siRNA	sirna	NN	O
-	-	HYPH	O
transfected	transfecte	VBN	O
cells	cell	NNS	O
,	,	,	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
poorly	poorly	RB	O
affect	affect	VBP	O
RICD	RICD	NNP	O
,	,	,	O
with	with	IN	O
Amb639752	Amb639752	NNP	O
,	,	,	O
11	11	CD	O
and	and	CC	O
14	14	CD	O
slightly	slightly	RB	O
reducing	reduce	VBG	O
it	-PRON-	PRP	O
Figure	figure	NN	O
9	9	CD	O
.	.	.	O

Conversely	conversely	RB	O
,	,	,	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
significantly	significantly	RB	O
rescued	rescue	VBD	O
the	the	DT	O
apoptotic	apoptotic	JJ	O
defect	defect	NN	O
of	of	IN	O
SAP	sap	NN	O
-	-	HYPH	O
deficient	deficient	JJ	O
T	t	NN	O
cells	cell	NNS	O
although	although	IN	O
not	not	RB	O
reaching	reach	VBG	O
control	control	NN	O
levels	level	NNS	O
.	.	.	O

At	at	IN	O
10âÂµM	10ââµm	CD	O
,	,	,	O
all	all	PDT	O
the	the	DT	O
new	new	JJ	O
molecules	molecule	NNS	O
showed	show	VBD	O
an	an	DT	O
efficacy	efficacy	NN	O
comparable	comparable	JJ	O
to	to	IN	O
Amb637952	Amb637952	NNP	O
and	and	CC	O
ritanserin	ritanserin	NNP	O
used	use	VBD	O
as	as	IN	O
positive	positive	JJ	O
reference	reference	NN	O
molecules	molecule	NNS	O
.	.	.	O

Conversely	conversely	RB	O
,	,	,	O
the	the	DT	O
serotonin	serotonin	JJ	O
antagonist	antagonist	NN	O
ketanserin	ketanserin	NNP	O
is	be	VBZ	O
inactive	inactive	JJ	O
,	,	,	O
excluding	exclude	VBG	O
the	the	DT	O
involvement	involvement	NN	O
of	of	IN	O
serotonin	serotonin	JJ	O
receptors	receptor	NNS	O
in	in	IN	O
rescuing	rescue	VBG	O
the	the	DT	O
RICD	RICD	NNP	O
in	in	IN	O
SAP	sap	NN	O
-	-	HYPH	O
deficient	deficient	JJ	O
T	t	NN	O
cells	cell	NNS	O
Figure	figure	NN	O
9	9	CD	O
.	.	.	O

DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
partially	partially	RB	O
restores	restore	VBZ	O
apoptosis	apoptosis	NN	O
in	in	IN	O
SAP	sap	NN	O
deficient	deficient	JJ	O
lymphocytes	lymphocyte	NNS	O
.	.	.	O

Lymphocytes	lymphocyte	NNS	O
from	from	IN	O
normal	normal	JJ	O
subjects	subject	NNS	O
were	be	VBD	O
transfected	transfecte	VBN	O
with	with	IN	O
control	control	NN	O
or	or	CC	O
SAP	sap	NN	O
specific	specific	JJ	O
siRNA	siRNA	.	O
â	â	NNP	O
control	control	NN	O
siRNA	sirna	NN	O
,	,	,	O
â	â	NNP	O
SAP	SAP	NNP	O
siRNA	siRNA	NNP	O
.	.	.	O

After	after	IN	O
4Â	4â	NN	O
days	day	NNS	O
,	,	,	O
the	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
restimulated	restimulate	VBN	O
with	with	IN	O
CD3	CD3	NNP	O

agonist	agonist	NN	O
OKT3	OKT3	NNP	O
10âng	10âng	CD	O
/	/	SYM	O
mL	mL	NNP	O
in	in	IN	O
presence	presence	NN	O
of	of	IN	O
respective	respective	JJ	O
inhibitor	inhibitor	NN	O
.	.	.	O

Vehicle	vehicle	NN	O
DMSO	DMSO	NNP	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
control	control	NN	O
.	.	.	O

Twenty	twenty	CD	O
-	-	HYPH	O
four	four	CD	O
hours	hour	NNS	O
later	later	RB	O
,	,	,	O
the	the	DT	O
%	%	NN	O
of	of	IN	O
cell	cell	NN	O
loss	loss	NN	O
was	be	VBD	O
evaluated	evaluate	VBN	O
by	by	IN	O
PI	PI	NNP	O
staining	staining	NN	O
.	.	.	O

Data	datum	NNS	O
are	be	VBP	O
the	the	DT	O
meanâÂ±âSEM	meanâÂ±âSEM	NNP	O
of	of	IN	O
nine	nine	CD	O
independent	independent	JJ	O
experiments	experiment	NNS	O
performed	perform	VBN	O
in	in	IN	O
triplicate	triplicate	NN	O
.	.	.	O

In	in	IN	O
summary	summary	NN	O
,	,	,	O
these	these	DT	O
data	datum	NNS	O
confirm	confirm	VBP	O
that	that	IN	O
the	the	DT	O
newly	newly	RB	O
identified	identify	VBN	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
can	can	MD	O
rescue	rescue	VB	O
RICD	RICD	NNP	O
susceptibility	susceptibility	NN	O
in	in	IN	O
T	T	NNP	O
cell	cell	NN	O
models	model	NNS	O
of	of	IN	O
XLP-1	XLP-1	NNP	O
suggesting	suggest	VBG	O
a	a	DT	O
putative	putative	JJ	O
use	use	NN	O
for	for	IN	O
XLP-1	XLP-1	NNP	O
therapy	therapy	NN	O
.	.	.	O

Previous	previous	JJ	O
studies	study	NNS	O
conducted	conduct	VBN	O
in	in	IN	O
our	-PRON-	PRP$	O
laboratory	laboratory	NN	O
demonstrated	demonstrate	VBD	O
that	that	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
DGK	DGK	NNP	O
activity	activity	NN	O
decreases	decrease	VBZ	O
chemotaxis	chemotaxis	NN	O
,	,	,	O
proliferation	proliferation	NN	O
,	,	,	O
migration	migration	NN	O
,	,	,	O
and	and	CC	O
invasion	invasion	NN	O
of	of	IN	O
many	many	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
lines	line	NNS	B
.	.	.	O

To	to	TO	O
evaluate	evaluate	VB	O
if	if	IN	O
our	-PRON-	PRP$	O
newly	newly	RB	O
synthetised	synthetise	VBN	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
were	be	VBD	O
effective	effective	JJ	O
in	in	IN	O
impairing	impair	VBG	O
cancer	cancer	NN	O
cell	cell	NN	O
migration	migration	NN	O
,	,	,	O
we	-PRON-	PRP	O
measured	measure	VBD	O
serum	serum	NNP	O
induced	induce	VBN	O
wound	wound	NN	O
healing	healing	NN	O
in	in	IN	O
MCF7	MCF7	NNP	O
breast	breast	NN	O
cancer	cancer	NN	O
cells	cell	NNS	O
in	in	IN	O
presence	presence	NN	O
of	of	IN	O
10Â	10Â	NNP	O
ÂµM	ÂµM	NNP	O
inhibitor	inhibitor	NN	O
.	.	.	O

In	in	IN	O
presence	presence	NN	O
of	of	IN	O
serum	serum	NN	O
,	,	,	O
none	none	NN	O
of	of	IN	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
is	be	VBZ	O
toxic	toxic	JJ	O
for	for	IN	O
MCF7	MCF7	NNP	O
cells	cell	NNS	O
even	even	RB	O
after	after	IN	O
prolonged	prolong	VBD	O
treatment	treatment	NN	O
data	datum	NNS	O
not	not	RB	O
shown	show	VBN	O
.	.	.	O

After	after	IN	O
15âh	15âh	CD	O
of	of	IN	O
treatment	treatment	NN	O
,	,	,	O
all	all	PDT	O
the	the	DT	O
newly	newly	RB	O
synthesised	synthesise	VBN	O
active	active	JJ	O
molecules	molecule	NNS	O
equally	equally	RB	O
reduced	reduced	JJ	O
cell	cell	NN	O
migration	migration	NN	O
when	when	WRB	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
vehicle	vehicle	NN	O
DMSO	DMSO	NNP	O
delaying	delay	VBG	O
wound	wound	NN	O
closure	closure	NN	O
Figure	Figure	NNP	O
10	10	CD	O
.	.	.	O

Novel	Novel	NNP	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
slow	slow	JJ	O
tumour	tumour	NN	O
cell	cell	NN	O
migration	migration	NN	O
.	.	.	O

MCF7	MCF7	NNP	O
monolayer	monolayer	NNP	O
was	be	VBD	O
wounded	wound	VBN	O
and	and	CC	O
treated	treat	VBN	O
for	for	IN	O
15âh	15âh	CD	O
with	with	IN	O
serum	serum	NN	O
in	in	IN	O
presence	presence	NN	O
of	of	IN	O
our	-PRON-	PRP$	O
new	new	JJ	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
10âÎ¼M	10âî¼m	CD	O
or	or	CC	O
vehicle	vehicle	NN	O
DMSO	DMSO	NNP	O
.	.	.	O

Results	result	NNS	O
are	be	VBP	O
expressed	express	VBN	O
as	as	IN	O
the	the	DT	O
percentage	percentage	NN	O
of	of	IN	O
wound	wound	NN	O
area	area	NN	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
initial	initial	JJ	O
area	area	NN	O
.	.	.	O

Data	datum	NNS	O
are	be	VBP	O
the	the	DT	O
meanâÂ±âSEM	meanâÂ±âSEM	NNP	O
of	of	IN	O
nine	nine	CD	O
independent	independent	JJ	O
experiments	experiment	NNS	O
.	.	.	O

Besides	besides	IN	O
being	be	VBG	O
in	in	IN	O
good	good	JJ	O
agreement	agreement	NN	O
with	with	IN	O
the	the	DT	O
notion	notion	NN	O
that	that	IN	O
DGKÎ±	DGKÎ±	NNP	O
is	be	VBZ	O
required	require	VBN	O
for	for	IN	O
cancer	cancer	NN	O
cells	cell	NNS	O
migration	migration	NN	O
,	,	,	O
this	this	DT	O
observation	observation	NN	O
indicates	indicate	VBZ	O
that	that	IN	O
our	-PRON-	PRP$	O
new	new	JJ	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
reduce	reduce	VBP	O
cancer	cancer	NN	O
cell	cell	NN	O
motility	motility	NN	O
,	,	,	O
suggesting	suggest	VBG	O
a	a	DT	O
potential	potential	JJ	O
utility	utility	NN	O
in	in	IN	O
a	a	DT	O
metastasis	metastasis	NN	O
setting	setting	NN	O
.	.	.	O

From	from	IN	O
the	the	DT	O
data	datum	NNS	O
obtained	obtain	VBN	O
,	,	,	O
it	-PRON-	PRP	O
is	be	VBZ	O
possible	possible	JJ	O
to	to	TO	O
identify	identify	VB	O
some	some	DT	O
key	key	JJ	O
pharmacophoric	pharmacophoric	JJ	O
points	point	NNS	O
crucial	crucial	JJ	O
for	for	IN	O
the	the	DT	O
biological	biological	JJ	O
activity	activity	NN	O
of	of	IN	O
the	the	DT	O
Amb	Amb	NNP	O
compounds	compound	NNS	O
on	on	IN	O
DGKs	dgk	NNS	O
namely	namely	RB	O
:	:	:	O
i	i	NN	O
a	a	DT	O
basic	basic	JJ	O
nitrogen	nitrogen	NN	O
;	;	,	O
ii	ii	LS	O
the	the	DT	O
methyl	methyl	NN	O
groups	group	NNS	O
at	at	IN	O
the	the	DT	O
2	2	CD	O
and	and	CC	O
6	6	CD	O
position	position	NN	O
of	of	IN	O
the	the	DT	O
indole	indole	NNP	O
nucleus	nucleus	NNP	O
,	,	,	O
and	and	CC	O
iii	iii	NNP	O
a	a	FW	O
hetero)aromatic	hetero)aromatic	JJ	O
ring	ring	NN	O
.	.	.	O

This	this	DT	O
information	information	NN	O
allows	allow	VBZ	O
us	-PRON-	PRP	O
to	to	TO	O
build	build	VB	O
a	a	DT	O
four	four	CD	O
-	-	HYPH	O
point	point	NN	O
pharmacophoric	pharmacophoric	JJ	O
model	model	NN	O
represented	represent	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
11	11	CD	O
superimposed	superimpose	VBN	O
with	with	IN	O
the	the	DT	O
minimised	minimise	VBN	O
structure	structure	NN	O
of	of	IN	O
compound	compound	NN	O
11	11	CD	O
.	.	.	O

Although	although	IN	O
,	,	,	O
we	-PRON-	PRP	O
are	be	VBP	O
not	not	RB	O
able	able	JJ	O
to	to	TO	O
evaluate	evaluate	VB	O
the	the	DT	O
importance	importance	NN	O
of	of	IN	O
the	the	DT	O
two	two	CD	O
carbonyl	carbonyl	NN	O
groups	group	NNS	O
,	,	,	O
it	-PRON-	PRP	O
represents	represent	VBZ	O
the	the	DT	O
first	first	JJ	O
attempts	attempt	NNS	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
identify	identify	VB	O
the	the	DT	O
minimum	minimum	JJ	O
structural	structural	JJ	O
request	request	NN	O
to	to	TO	O
interact	interact	VB	O
with	with	IN	O
DGK	DGK	NNP	O
catalytic	catalytic	JJ	O
site	site	NN	O
considering	consider	VBG	O
the	the	DT	O
molecular	molecular	JJ	O
structure	structure	NN	O
of	of	IN	O
the	the	DT	O
four	four	CD	O
most	most	RBS	O
active	active	JJ	O
inhibitors	inhibitor	NNS	O
discovered	discover	VBD	O
to	to	IN	O
date	date	NN	O
Amb639752	Amb639752	NNP	O
,	,	,	O
ritanserin	ritanserin	NNP	O
,	,	,	O
R59022	R59022	NNP	O
,	,	,	O
and	and	CC	O
R59949	R59949	NNP	O
.	.	.	O

We	-PRON-	PRP	O
feel	feel	VBP	O
that	that	IN	O
this	this	DT	O
model	model	NN	O
might	may	MD	O
be	be	VB	O
useful	useful	JJ	O
to	to	TO	O
identify	identify	VB	O
novel	novel	JJ	O
compounds	compound	NNS	O
active	active	JJ	O
on	on	IN	O
DGKÎ±	DGKÎ±	NNP	O
through	through	IN	O
more	more	RBR	O
targeted	target	VBN	O
virtual	virtual	JJ	O
screening	screening	NN	O
campaigns	campaign	NNS	O
,	,	,	O
overcoming	overcome	VBG	O
the	the	DT	O
current	current	JJ	O
scaffolds	scaffold	NNS	O
.	.	.	O

Proposed	propose	VBN	O
pharmacophoric	pharmacophoric	JJ	O
model	model	NN	O
.	.	.	O

As	as	IN	O
a	a	DT	O
key	key	JJ	O
component	component	NN	O
of	of	IN	O
several	several	JJ	O
signal	signal	JJ	O
transduction	transduction	NN	O
pathways	pathway	NNS	O
,	,	,	O
DGKÎ±	DGKÎ±	NNP	O
represent	represent	VBP	O
an	an	DT	O
emerging	emerge	VBG	O
pharmacological	pharmacological	JJ	O
target	target	NN	O
.	.	.	O

We	-PRON-	PRP	O
have	have	VBP	O
demonstrated	demonstrate	VBN	O
the	the	DT	O
efficacy	efficacy	NN	O
of	of	IN	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
for	for	IN	O
XLP-1	XLP-1	NNP	O

treatment	treatment	NN	B
,	,	,	O
while	while	IN	O
others	other	NNS	O
have	have	VBP	O
proposed	propose	VBN	O
them	-PRON-	PRP	O
for	for	IN	O
cancer	cancer	NN	O
treatment	treatment	NN	B
and	and	CC	O
to	to	TO	O
remove	remove	VB	O
immune	immune	NN	O
-	-	HYPH	O
checkpoints	checkpoint	NNS	O
promoting	promote	VBG	O
immune	immune	JJ	O
vigilance	vigilance	NN	O
against	against	IN	O
cancer	cancer	NN	B
.	.	.	O

Commercially	commercially	RB	O
available	available	JJ	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
are	be	VBP	O
limited	limit	VBN	O
by	by	IN	O
poor	poor	JJ	O
specificity	specificity	NN	B
,	,	,	B
and	and	CC	O
pharmacokinetic	pharmacokinetic	JJ	B
.	.	.	O

The	the	DT	O
CU-3	CU-3	NNP	O

molecule	molecule	NN	O
described	describe	VBN	O
by	by	IN	O
other	other	JJ	O
features	feature	NNS	O
a	a	DT	O
noteworthy	noteworthy	JJ	O
activity	activity	NN	O
and	and	CC	O
specificity	specificity	NN	O
but	but	CC	O
its	-PRON-	PRP$	O
reactive	reactive	JJ	O
chemical	chemical	NN	O
structure	structure	NN	O
make	make	VBP	O
unlikely	unlikely	JJ	O
an	an	DT	O
inÂ	inÂ	NNP	O
vivo	vivo	NN	O
use	use	NN	B
.	.	.	O

With	with	IN	O
intent	intent	NN	O
of	of	IN	O
developing	develop	VBG	O
molecules	molecule	NNS	O
suitable	suitable	JJ	O
for	for	IN	O
therapeutic	therapeutic	JJ	O
use	use	NN	O
we	-PRON-	PRP	O
selected	select	VBD	O
Amb639752	Amb639752	NNP	O
as	as	IN	O
a	a	DT	O
novel	novel	JJ	O
inhibitor	inhibitor	NN	O
with	with	IN	O
remarkable	remarkable	JJ	O
DGKÎ±	DGKÎ±	NNP	O
activity	activity	NN	O
.	.	.	O

Amb639752	Amb639752	NNP	O
also	also	RB	O
features	feature	VBZ	O
improved	improve	VBN	O
selectivity	selectivity	NN	O
for	for	IN	O
DGKÎ±	DGKÎ±	NNP	O
as	as	IN	O
it	-PRON-	PRP	O
does	do	VBZ	O
not	not	RB	O
affect	affect	VB	O
serotonin	serotonin	NN	O
signalling	signal	VBG	B
.	.	.	O

Despite	despite	IN	O
numerous	numerous	JJ	O
efforts	effort	NNS	O
a	a	DT	O
structure	structure	NN	O
of	of	IN	O
mammalian	mammalian	JJ	O
DGKs	dgk	NNS	O
is	be	VBZ	O
still	still	RB	O
missing	miss	VBG	O
,	,	,	O
thus	thus	RB	O
we	-PRON-	PRP	O
decided	decide	VBD	O
to	to	TO	O
explore	explore	VB	O
the	the	DT	O
structureâactivity	structureâactivity	NN	O
relationship	relationship	NN	O
of	of	IN	O
this	this	DT	O
molecule	molecule	NN	O
to	to	TO	O
improve	improve	VB	O
its	-PRON-	PRP$	O
activity	activity	NN	O
and	and	CC	O
pave	pave	VB	O
the	the	DT	O
way	way	NN	O
for	for	IN	O
further	further	JJ	O
developments	development	NNS	O
.	.	.	O

Our	-PRON-	PRP$	O
efforts	effort	NNS	O
allowed	allow	VBD	O
us	-PRON-	PRP	O
to	to	TO	O
build	build	VB	O
a	a	DT	O
pharmacophoric	pharmacophoric	JJ	O
model	model	NN	O
for	for	IN	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
characterised	characterise	VBN	O
by	by	IN	O
three	three	CD	O
required	require	VBN	O
features	feature	NNS	O
.	.	.	O

We	-PRON-	PRP	O
also	also	RB	O
characterised	characterise	VBD	O
a	a	DT	O
set	set	NN	O
of	of	IN	O
novel	novel	JJ	O
compounds	compound	NNS	O
with	with	IN	O
improved	improve	VBN	O
IC50	IC50	NNP	O
in	in	IN	O
the	the	DT	O
low	low	JJ	O
ÂµM	ÂµM	NNP	O
range	range	NN	O
and	and	CC	O
identified	identify	VBD	O
the	the	DT	O
most	most	RBS	O
profitable	profitable	JJ	O
synthetic	synthetic	JJ	O
route	route	NN	O
for	for	IN	O
them	-PRON-	PRP	O
.	.	.	O

The	the	DT	O
mode	mode	NN	O
of	of	IN	O
DGKÎ±	DGKÎ±	NNP	O
inhibition	inhibition	NN	O
by	by	IN	O
those	those	DT	O
molecules	molecule	NNS	O
is	be	VBZ	O
still	still	RB	O
unknown	unknown	JJ	O
apart	apart	RB	O
for	for	IN	O
ritanserin	ritanserin	NNP	O
,	,	,	O
which	which	WDT	O
binds	bind	VBZ	O
at	at	IN	O
the	the	DT	O
same	same	JJ	O
time	time	NN	O
the	the	DT	O
DGKÎ±	DGKÎ±	NNP	O
catalytic	catalytic	JJ	O
accessory	accessory	JJ	O
domain	domain	NN	O
and	and	CC	O
the	the	DT	O
C1	C1	NNP	O
domain	domain	NN	O
putatively	putatively	RB	O
promoting	promote	VBG	O
a	a	DT	O
close	close	JJ	O
inactive	inactive	JJ	O
conformation	conformation	NN	B
.	.	.	O

The	the	DT	O
second	second	JJ	O
-	-	HYPH	O
generation	generation	NN	O
inhibitors	inhibitor	NNS	O
we	-PRON-	PRP	O
described	describe	VBD	O
in	in	IN	O
this	this	DT	O
work	work	NN	O
maintain	maintain	VB	O
the	the	DT	O
specificity	specificity	NN	O
of	of	IN	O
Amb639752	Amb639752	NNP	O
as	as	IN	O
they	-PRON-	PRP	O
not	not	RB	O
affect	affect	VBP	O
DGKÎ¶	dgkî¶	IN	O
,	,	,	O
the	the	DT	O
predominant	predominant	JJ	O
isoform	isoform	NN	O
of	of	IN	O
lymphocytes	lymphocyte	VBZ	B
and	and	CC	O
the	the	DT	O
broadly	broadly	RB	O
expressed	express	VBN	O
DGKÎ¸	dgkî¸	JJ	B
.	.	.	O

Those	those	DT	O
DGKÎ±	DGKÎ±	NNP	O
inhibitors	inhibitor	NNS	O
are	be	VBP	O
active	active	JJ	O
in	in	IN	O
a	a	DT	O
lymphocyte	lymphocyte	RB	O
based	base	VBN	O
XLP-1	XLP-1	NNP	O
assay	assay	NN	O
and	and	CC	O
in	in	IN	O
a	a	DT	O
cancer	cancer	NN	O
cell	cell	NN	O
migration	migration	NN	O
assay	assay	NN	O
,	,	,	O
holding	hold	VBG	O
the	the	DT	O
promise	promise	NN	O
for	for	IN	O
a	a	DT	O
potential	potential	JJ	O
therapeutic	therapeutic	JJ	O
application	application	NN	O
.	.	.	O

However	however	RB	O
,	,	,	O
their	-PRON-	PRP$	O
efficacy	efficacy	NN	O
is	be	VBZ	O
still	still	RB	O
to	to	TO	O
be	be	VB	O
determined	determine	VBN	O
in	in	IN	O
inÂ	inÂ	NNP	O
vivo	vivo	NN	O
models	model	NNS	O
of	of	IN	O
disease	disease	NN	O
where	where	WRB	O
some	some	DT	O
of	of	IN	O
the	the	DT	O
parental	parental	JJ	O
compounds	compound	NNS	O
showed	show	VBD	O
efficacy	efficacy	NN	O
but	but	CC	O
poor	poor	JJ	O
pharmacokinetic	pharmacokinetic	JJ	B
,	,	,	B
.	.	.	O

